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Abstract
Facial skin cancer secondary to surgical treatment may be distressing due to the
malignancy itself and from the consequences of its treatment. A visible postsurgical scar
is an obvious reminder of the condition. This investigation sought to broaden our
understanding of facial scarring and develop a novel tool for its objective evaluation. To
this end, skin cancer as the most common etiology of facial scarring was reviewed. The
scar scale literature was evaluated in the context of assessing scars through a
biopsychosocial lens. Finally, the development of a novel scar scale was presented.
Thirty-four individuals completed 13,056 ratings using a novel scar scale – the Scar
Camouflage Scale (SCS). Preliminary data demonstrated intra-rater agreement of 0.74 0.92 and between-rater agreement of 0.78 - 0.96. In conclusion, through rigorous
methodology this investigation provides preliminary support for the establishment and
use of the Scar Camouflage Scale (SCS). These results provide the empiric basis for
wholistic scar evaluation.
Keywords: Skin Cancer, Non-melanoma, Facial Scar, Scar Scale, Scar Evaluation
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Summary for a Lay Audience
Facial skin cancer is an anxiety provoking condition. Not only is the diagnosis
distressing, but so too is the consequence of its treatment which is most commonly
surgery. Regardless of location, every surgery will result in some form of scarring.
When this affects the face, scarring is a visible daily reminder of the condition, one that
may also impact one’s physical appearance and body image.
Many factors contribute to how a scar impacts an individual’s body image. Few
research studies have been able to holistically understand these factors, or determine how
the scar itself contributes to the person’s overall body image and self-perception. One of
the main difficulties lies in the way scars are currently evaluated. The research conducted
has been somewhat inconsistent and we remain without a standardized way to measure
scars.
This investigation sought to improve our understanding of facial scarring and
develop a new scar measurement tool. To achieve these goals, we reviewed the most
common reason that an individual might acquire a facial scar – facial skin cancer. We
then assessed how scars affect a person relative to their psychological and social impact.
To this end, we reviewed all relevant literature and aimed to place these in the context of
what is termed the “biopsychosocial” model of health. Finally, we presented the results
of a study that sought to develop a new scar scale called the Scar Camouflage Scale
(SCS).
The results of this study demonstrate that individuals can reliably measure scars
using the SCS, even when different individuals measure the same scar. These data
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provide the necessary evidence to support further research using the SCS and apply this
research to help understand the comprehensive impact of facial scarring.
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Chapter 1: Introduction and Background
Introduction
Non-melanoma skin cancer is the most common form of cancer with an estimated
annual incidence of 80,000 cases in Canada per year (Canadian Cancer Society, 2014).
The head and neck regions are the most common areas of the body affected (Norval et al.,
2014). Given the visibility of a skin cancer lesion on the face, it is not surprising that
these lesions result in some form of facial disfigurement. A team of investigators at
Johns Hopkins University (Baltimore, Maryland, USA) characterized this facial
disfigurement an “attractiveness penalty” – largely influenced by the size, depth and
location of the facial lesion (Cassileth et al., 1983; Godoy et al., 2011). In addition to the
“attractiveness penalty”, individuals with facial lesions have perceived negative affect
resulting in an overall “social penalty” that decreases observer comfort when conversing
with these individuals socially (Dey, Ishii, Byrne, et al., 2015). Accordingly, removal of
the skin cancer and subsequent repair of the removal defect is critical to normalizing
these individuals’ appearance and restoring their sense of well-being and social
functioning (Godoy et al., 2011).
Impact of Facial Skin Scarring
Like all surgery, removal of a skin cancer and repair of the subsequent defect
results in some degree of surgical scarring. A paper published by Sobanko and colleagues
(2015) reviews the impact of skin cancer vis-à-vis an individual’s appearance (Sobanko
et al., 2015). To summarize, individuals with a facial scar are stigmatized and more
likely to be judged as dysfunctional, dishonest, unsuitable for employment, unintelligent,
and unattractive (Borah & Rankin, 2010; Ishii et al., 2009; Kim et al., 2013; Rankin &
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Borah, 2003; Sobanko et al., 2015). Perceived stigma by those with a facial lesion or scar
can result in an impairment of communication, and restrictions of personal relationships
in addition to social and vocational activities (Brown et al., 2010; Sobanko et al., 2015).
Importantly, it is the individuals’ own subjective perception of their scar visibility and not
their observed degree of scarring that directly impairs their psychosocial functioning
(Brown et al., 2010; Sobanko et al., 2015). Thus, skin cancer surgery often results in
appearance-related anxiety resulting in impairments of quality of life and financial
stability – with many going on employment disability due to the psychosocial burden of
disfigurement (Sobanko et al., 2015). Finally, facial disfigurement in the form of a scar is
so distressing that >50% of adults would risk a 7% chance of death, and more than 13%
of adults would accept a 30-45% risk of death, to obtain a “normal” face (Borah &
Rankin, 2010; Sobanko et al., 2015).
The burden of facial skin cancer is substantial. Facial skin cancer not only
imparts an “attractiveness penalty” in and of itself, but the resultant scar from its removal
may also perpetuate psychosocial impairment due to a perceived facial disfigurement. It
is not surprising that a well-executed reconstruction following the removal of a facial skin
cancer can substantially improve an individual’s overall quality of life (Dey, Ishii,
Boahene, et al., 2015). But what constitutes a “well-executed reconstruction”? This
largely boils down to achieving a “good scar”. The difficulty herein is that a “good scar”
is similar to the perception of “talent”; you know a “good scar” when you see it – or
rather when you do not see it. Furthermore, it is impossible to ignore the personal factors
and context of the individual affected by the scar. A young facial model may be severely
traumatized by a small objectively minimal facial scar whereas an older individual with
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substantial facial hair may be relatively unfazed by even a large objectively obvious
facial scar. It is the delicate balance of objective scar features, personal factors, and the
overall context of the individual affected that truly determine the impact of a facial scar
and its burden to the individual.

To add to this complexity, a paucity of consistency

exists in the objective scar evaluation literature (Durani et al., 2009).
Objective Scar Scaling
When reviewing the scar scaling literature (Durani et al., 2009), a point of
disparity relates to which scar features should be evaluated and how they each contribute
to the camouflage of the scar and its overall impact on an individual’s facial appearance.
In fact, without a clear understanding of which scar dimensions need to be evaluated and
the mechanism to evaluate them, the logical progression of determining the association of
each scar dimension on overall scar camouflage or acceptability cannot be done. What
has been evaluated thus far are variations on scar dimensions which include how wide or
stretched a scar appears, its height relative to the surrounding skin, its discolouration
relative to the surrounding skin, any irregularities in its appearance or distortion of
surrounding structures, and any evidence of surgery – i.e., suture marks. Figures 1.1 and
1.2 illustrate examples of poorly camouflaged and well-camouflaged scars, respectively.
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Figure 1.1: Obvious Upper Lip/Cheek Scar

Note. A poorly camouflaged scar of the right cheek and upper lip many years
following a traumatic facial injury.

Figure 1.2: Well-Camouflaged Left Upper Eyelid Scar: (a) prior to and (b) 3-months
following surgical excision

a.

b.

Note. Purple markings indicate incision lines for removal and reconstruction.

The previously described scar dimensions have been defined in various forms in
the aforementioned efforts of generating an empirically validated objective scar
evaluation scale. The resultant scales from this body of research have included the
Vancouver Scar Scale, Patient and Observer Scar Scale, Manchester Scar Scale, Stony
Brook Scar Evaluation Scale, and SCAR scale (Durani et al., 2009; Idriss & Maibach,
4

2009; Perry et al., 2010; Roques & Téot, 2007; Vercelli et al., 2003). While each of these
scales demonstrates empiric reliability, they vary in the dimensions being scaled and the
methods used to scale these dimensions (Brandt et al., 2009; Perry et al., 2010). Thus, we
remain without a reliable tool to objectively characterize observed scar outcomes.
Statement of Problem
Without a reliable, consistent, and empirically sound means of objectively
evaluating scars it is impossible to pursue research that relates objective scar outcomes
with the personal experience of a scar. Furthermore, and more practically speaking, it is
similarly impossible to provide empiric recommendations on how to optimize
postsurgical scarring.
To provide context, this thesis will begin by exploring the contemporary
management of skin cancer, as this is the most common means by which an individual
might obtain a facial scar. To integrate and understand the impact of facial scarring on an
individual’s overall wellbeing, facial scarring will be reviewed through the lens of the
World Health Organization’s International Classification of Functioning, Disability, and
Health (ICF) (Stephens, 2001). We will then describe the preliminary validation of a
novel scar assessment instrument. Finally, we will strive to integrate the preceding
discussions and define potential objectives for future investigation.
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Chapter 2: Contemporary Management of Non-Melanoma Skin Cancer
“Non-melanoma skin cancer” represents a broad group of cutaneous
malignancies. Included in this category are common Keratinocyte Carcinomas (KC) and
rare neoplasms such as Merkel Cell Carcinoma, Adnexal Carcinomas, and Cutaneous
Sarcomas. Although divergent in cell lineage and presentation, these malignancies
primarily occur in the head and neck region and undoubtedly result in some degree of
facial disfigurement and morbidity. Facial plastic surgeons have the unique opportunity
to both cure a patient of a potentially life threatening malignancy and also improve their
overall quality of life through a well-executed post-ablative reconstruction (Dey, Ishii,
Boahene, et al., 2015). This chapter endeavours to provide the reader with a
contemporary overview of cutaneous neoplasms that present in the head and neck region.
Keratinocyte Carcinomas
Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) represent the
two most common skin malignancies and are frequently lumped together under the
umbrella term “Non-Melanoma Skin Cancer”. These two cutaneous malignancies share a
cellular lineage with keratinocytes and are thus more accurately termed Keratinocyte
Carcinomas (Albert & Weinstock, 2003). As a category, Keratinocyte Carcinomas are the
most common malignancies worldwide – with an annual incidence that exceeds all other
malignancies combined (Rogers et al., 2015). The incidence of KC continues to grow
with well-over 3-million treatments for KC in the United States each year (Rogers et al.,
2015). While Keratinocyte Carcinomas are typically well managed and only rarely do
they metastasize, these lesions can result in substantial morbidity.
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Aetiology
While the risk of developing KC is dependent on genotypic, phenotypic, and
environmental factors, it is well-established that ultraviolet (UV) solar radiation is the
greatest single risk factor for the development of KC (Madan et al., 2010). UVB (290–
320 nm) is considered more carcinogenic than UVA (320–400 nm) as it is completely
absorbed in the skin and results in the mutation of tumour suppressor genes (Gailani et
al., 1996). UVA which penetrates deeper than UVB also plays a role as it activates the
signal transduction molecule protein C- kinase, and also impairs the activity of tumour
suppressor T-cells leading to tumour expansion and a failed immune response (Matsui &
DeLeo, 1991; Nghiem et al., 2002). Cumulative sun exposure may be more causally
related to the development of SCC in that it results in UV-induced DNA damage and
subsequent p53 gene mutations (Lee & Miller, 2009; Madan et al., 2010). Mutations of
the p53 gene can also be found in up to 50 percent of BCCs (Rubin et al., 2005). In
contrast to SCC, intense intermittent recreational sun exposure (i.e., resulting in sun
burns) and exposure during childhood may be more central to the development of BCCs
(Lee & Miller, 2009; Madan et al., 2010). BCCs frequently demonstrate mutations of
chromosome 9q resulting in Patched (PTCH) gene mutations and subsequently induced
hedgehog (Hh) signalling (Lee & Miller, 2009). It is this hedgehog signalling pathway
that is targeted by the systemic Hh inhibitors Vismodegib and Sonidegib – FDA
approved for the treatment of advanced BCC (Chen et al., 2016; Sekulic et al., 2012).
Other risks factors for the development of KC appear in Table 2.1.
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Table 2.1: Risk factors for the development of Keratinocyte Carcinomas*
Risk Factor:
UV radiation (sun exposure, tanning beds)
Ionizing radiation
Immunosuppression
Human Papillomavirus
Smoking
Chronic scarring / inflammation
Exposure to polycyclic hydrocarbons
Phototherapy with psoralens (PUVA therapy)
Photosensitising drugs (i.e., Fluoroquinolones)
Arsenic ingestion
Syndromes:
Xeroderma Pigmentosum
Oculocutaneous albinism
Nevoid BCC syndrome/Gorlin Syndrome/Basal cell nevus syndrome
Epidermodysplasia verruciformis
Dystrophic epidermoylsis bullosa
Muirre-Torre syndrome
KID (keratosis, icthyosis, deafness)
Fanconi anemia
Rothmund-Thompson syndrome
Werner syndrome

Note. Risk factors and syndromes that increase the risk of developing Keratinocyte
Carcinoma. (*Adapted from Lee & Miller, 2009 and Madan et al., 2010).
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Clinical Features and Work-Up
Common clinical features of Keratinocyte Carcinomas appear in Table 2.2. Due
to the relationship of KCs and UV light exposure, these lesions occur most
frequently in the head and neck region. Of the KCs, approximately 75% are BCCs and
25% are SCCs.

Table 2.2: Common Clinical Features of Keratinocyte Carcinomas*
Red Flags:
A new rapidly growing lesion
A lesion that is changing in size or shape
A non-healing sore
Nonspecific features that may be seen in Keratinocyte Carcinoma:
Nodular growth
Irregular border
Elevation
Erosion, ulceration, crust
Bleeding
Erythema with sharp borders
Features suggestive of Basal Cell Carcinoma:
Translucent (pearly or waxy) appearance
Telengiectasias (fine, tortuous vessels visible near the surface)
Raised (“rolled”) border
Pigment without a netlike pattern
Scar like appearance
Erythema with pinpoint erosions
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Features suggestive of Squamous Cell Carcinoma:
Adherent scale or crust
Cutaneous horn
Extensive erosion of tissue

Note. Common clinical features of Keratinocyte Carcinomas including those that may be
more suggestive of BCC and SCC. (*Adapted from Albert & Weinstock, 2003)

Basal Cell Carcinoma
BCCs are clinically categorized as nodular, superficial, and infiltrative or
sclerosing subtypes (see Figures 2.1 – 2.7). Nodular BCCs are most common and present
as waxy raised papules or nodules with telengiectasias (see Figure 2.1).

Figure 2.1: Nodular BCCs: Left upper lip nodular pigmented BCC (a) and nodular BCC of the right
ala (b).

a.

b.

Superficial BCCs grow horizontally and present as thin erythematous plaques
with variable scale and telengiectasias (see Figure 2.2).
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Figure 2.2: Superficial BCCs: Superficial pigmented BCC of the scalp (a) and a large superficial BCC of
the right temple (b)

a.

b.

Sclerosing BCCs are ill-defined, indurated red or white plaques that can be
slightly elevated or depressed and atrophic (see Figure 2.3).

Figure 2.3: Sclerosing BCCs: the forehead (a) and the right neck (b)

a.

b.
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Cutaneous Squamous Cell Carcinoma
Invasive SCC of the skin frequently presents as an erythematous, keratotic papule,
plaque, or nodule occurring in a background of actinic damage (see Figure 2.4).

Figure 2.4: Cutaneous SCCs: the scalp (a), the left cheek (b), left ear (c), and left temple/cheek (d).

a.

c.

b.

d.

These can demonstrate ulceration and patients will often describe a history of an
intermittently bleeding and non-healing sore. Actinic Keratosis and Bowen’s Disease
(SCC in situ) are considered precursor lesions to invasive SCC and frequently present as
a well-demarcated erythematous, scaly plaque (Albert & Weinstock, 2003).
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Management
Biopsy. Any clinically suspicious lesion should be biopsied. While multiple
biopsy techniques have been advocated, a 3 mm full-thickness punch biopsy provides the
greatest histologically diagnostic information and is thus recommended for any
suspicious lesion. Diagnostic imaging is reserved for clinically aggressive lesions to
determine the extent of invasion or to help evaluate for distant metastasis on the basis of
clinical suspicion or clinically palpable adenopathy. It is important to recognize that SCC
of the lip is considered an oral cancer and accordingly requires clinical and prudent
radiographic evaluation of regional lymphatics.
Resection of the Primary Malignancy. The primary goal in the treatment of
BCC and SCC is to cure the patient of their malignancy while limiting both tumour and
iatrogenic morbidity. Further to these goals, the National Comprehensive Cancer
Network (NCCN) provides Clinical Practice Guidelines for the evaluation and
management of Non-Melanoma Skin Cancers. These guidelines are up-to-date and
established by group consensus based on currently available evidence. Guidelines are
available at www.NCCN.org (National Comprehensive Cancer Network [NCCN], 2019a,
2019b).
As the majority of cutaneous malignancies occur in the head and neck region our
discussion will focus on cutaneous malignancies arising in this area. The treatment of
BCCs and SCCs is guided principally by the risk of local recurrence and/or disease
progression. The NCCN indicates that within the head and neck, non-melanoma skin
cancers that are most likely to recur present in the central face, are >1 cm in diameter,
are clinically poorly defined, recurrent lesions, occur in areas of previous radiation, or
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occur amongst patients that are immunosuppressed.

In the case of SCC, tumours >6

mm in the central face, rapidly growing tumours, or those that demonstrate neurologic
symptoms (i.e., anaesthesia, motor dysfunction) are also considered high-risk (NCCN,
2019a).
For high-risk BCCs and SCCs (with no evidence of metastasis) the NCCN
recommends management via Mohs micrographic surgery, resection with complete
circumferential margin assessment (i.e., intraoperative frozen section analysis), standard
excision with wide margins (4-6 mm) and post-operative margin assessment, or radiation
therapy for non-surgical candidates (NCCN, 2019a). For standard surgical excision,
Wolf and Zitelli (1987) demonstrated that for well-defined BCCs less than 2 cm in
diameter, excision with 4 mm clinical margins resulted in complete removal in more than
95% of cases. Wider surgical margins are recommended for SCCs whereby high-risk
SCCs measuring <1 cm, 1-1.9 cm, or >2 cm in diameter require clinical margins of 4, 6,
and 9 mm, respectively, when treated via standard surgical excision with post-operative
margin assessment (Brodland & Zitelli, 1992).
As per the NCCN guidelines, low-risk BCCs and SCCs can be managed via
electrodessication and curettage (excluding terminal hair-bearing areas) or via standard
excision with 4-6 mm margins and post-operative margin assessment (NCCN, 2019a,
2019b). For non-surgical candidates radiation therapy is recommended.
Incomplete Excisions and Aggressive Features on Pathology. Re-excision via
Mohs micrographic surgery or resection with complete circumferential margin
assessment (i.e., intraoperative frozen section analysis) is recommended for any BCC or
SCC that has been incompletely excised in the head and neck region (NCCN, 2019a,
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2019b). For those patients that are non-surgical candidates, or amongst those lesions
where further surgery is not possible, radiation therapy is recommended (NCCN, 2019a,
2019b). Adjuvant radiation therapy is also recommended for BCCs or SCCs
demonstrating perineural or lymphovascular involvement (NCCN, 2019a, 2019b).
Advanced Disease. Patients presenting with advanced BCCs or SCCs including
those with regional lymphatic involvement benefit from evaluation and management by a
multidisciplinary tumour board. NCCN guidelines at www.NCCN.org provide direction
with respect to the management of advanced keratinocyte carcinomas.
The incidence of metastatic BCC ranges from 0.0028 to 0.55 percent. Systemic
therapy in the form of Hedgehog (Hh) pathway inhibitors (i.e., Vismodegib, Sonidegib)
can be considered amongst any patient presenting with nodal or distant metastatic BCC
(NCCN, 2019a). This is also a treatment option for patients with recurrent BCC
following resection and adjuvant radiation, or amongst patients who are not candidates
for either surgery or radiation (NCCN, 2019a).
Metastatic SCC of the skin occurs with an incidence of approximately 2 to 6
percent (Mokhtar, 2009). The lip and ear represent the sites at highest risk for metastasis
in primary SCC with an incidence of 10 to 14 percent (Mokhtar, 2009). It is important to
note that recurrent SCC has a 30% incidence of metastasis emphasizing the need for
adequate primary control. Neck dissection and adjuvant radiation therapy is
recommended for SCCs with regional lymph node involvement and the extent of
dissection is dependent on lymph node size, lymph node number, and node location (i.e.,
parotid, ipsilateral neck, contralateral neck) (NCCN, 2019b). Concurrent systemic
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chemotherapy is recommended for any patient demonstrating extracapsular extension of
tumour on lymphadenectomy (NCCN, 2019b).
Less Common Non-Melanoma Skin Cancers
Merkel Cell Carcinoma
Merkel Cell Carcinoma (MCC) is an uncommon cutaneous neuroendocrine
carcinoma. While it remains relatively uncommon, the annual incidence has risen 5-fold
over the past 30 years (Tetzlaff & Nagarajan, 2018). In 2011, the incidence in the United
States was 7.9 cases per 1 million persons (Tetzlaff & Nagarajan, 2018). MCC primarily
affects Caucasian men at sites of chronic sun exposure in their 7th to 9th decade of life.
Immunosuppression is also considered a major risk factor for the development of MCC
(Tetzlaff & Nagarajan, 2018). MCC is an aggressive malignancy with a five year
survival rate of 50.6% for those with primary disease, 35.4% for those with regional
lymph node involvement, and 13.5% for those with distant metastases (Harms et al.,
2016).
The cell of origin of MCC is unknown and potentially includes epidermal stem
cells, B-cells, and fibroblasts. A novel human polyomavirus named Merkel Cell
Polyomavirus (MCPyV) can be detected in 60-80% of Merkel Cell Tumours (Feng et al.,
2008). MCPyV works through a variety of mechanisms resulting in inhibited tumour
suppressor function and carcinomatous cellular proliferation (Tetzlaff & Nagarajan,
2018).
Clinical Features and Work-Up. MCC presents as an asymptomatic, rapidly
growing, firm, red, pink, purple, or skin-coloured nodule (see Figures 2.13 – 2.15) (Heath
et al., 2008). Heath and colleagues proposed the AEIOU acronym to represent lesions
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that are Asymptomatic and Expanding rapidly amongst Immunosuppressed fair skin
individuals Older than 50 years at UV-exposed sites (Heath et al., 2008). In spite of
awareness of MCC and clinical vigilance its varied appearance results in most MCCs
being diagnosed histopathologically on biopsy when differentiated from other small blue
cell tumours on positive cytokeratin 20 (CK20) and negative thyroid transcription factor
1 (TTF-1) immunohistochemistry – differentiating it from small cell lung cancer. At time
of presentation, 65% of patients present with local disease, 26% of patients present with
regional lymph node metastases, and 8% present with distant metastases (Tetzlaff &
Nagarajan, 2018).

Figure 2.5: Merkel Cell Carcinomas: the left cheek (a), left forehead (b), and right
upper eyelid (c)

a.

b.

c.

Management. Work-up and management is guided by the most up-to-date
NCCN guidelines available from www.NCCN.org (NCCN, 2019c). The authors
recommend diagnostic imaging to evaluate for regional lymph node involvement and
distant metastasis for any patient diagnosed with MCC. For patients presenting with
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clinically palpable lymph nodes, these should be biopsied via fine needle aspiration
biopsy (FNAB) or core biopsy. Evaluation by a multidisciplinary tumour board should
be strongly considered.
The latest NCCN guidelines recommend sentinel lymph node biopsy (SLNB)
prior to definitive surgical excision (NCCN, 2019c). One third of patients presenting
with clinically negative lymph nodes are found to have micrometastases on SLNB
(Santamaria-Barria et al., 2013). Recurrence occurred in 56% of SLNB-positive and 39%
of SLNB-negative patients (Santamaria-Barria et al., 2013). It is important to note that
SLNB is less consistent in the head and neck region due to variability in nodal drainage
which can result in a false-negative SLNB (Willis & Ridge, 2007). SLNB does however
remain useful in guiding the dose and region of adjuvant radiation which is recommended
for all patients with MCC except perhaps for those presenting in immunocompetent
patients with <1 cm lesions that have been widely excised with no lymphovascular or
perineural invasion.
Once SLNB has been performed, the primary tumour requires resection with 1 to
2 cm margins to the investing fascia as recommended by the National Comprehensive
Cancer Network (2019c). In the head and neck region this is typically best performed via
Mohs surgery, modified Mohs surgery, or complete circumferential peripheral and deepmargin assessment (NCCN, 2019c). Neck dissection should be considered for any
patient presenting with regional lymph node involvement diagnosed on FNAB, core
biopsy, or SLNB – these patients require evaluation by a multidisciplinary tumour board
(NCCN, 2019c). Radiation to the primary site and involved nodal basin is recommended
for any patient with nodal involvement (NCCN, 2019c).

18

Radiation therapy is recommended for the majority of patients presenting with
MCC in an adjuvant fashion to the primary tumour site (NCCN, 2019c). For patients
with head and neck region MCC, radiation to the nodal basin should be considered even
amongst those with negative SLNB due to the aforementioned risk of a false-negative
result. These recommendations are based on the NCCN guidelines (2019c) which
indicate that adjuvant radiation therapy decreases local recurrence and significantly
improves overall survival.
Adnexal Carcinomas of the Skin
Adnexal carcinomas are rare with an annual incidence of approximately 1 per 20
million persons in the United States (Blake et al., 2010). While rare, the incidence of
these tumours has tripled over the past 30 years (Blake et al., 2010). Similar to Merkel
Cell Carcinoma, adnexal carcinomas occur most frequently amongst elderly Caucasian
males. This category of tumour includes carcinomas of the eccrine and apocrine glands,
carcinomas of the hair follicle, and carcinomas of the sebaceous glands. Our review of
these lesions will focus on those most frequently affecting the head and neck region and
appear summarized in Tables 2.3 – 2.5.
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Table 2.3: Eccrine and Apocrine Gland Carcinomas*
Common

Gender

Decade

Site
Mucinous carcinoma

Face /

Clinical

Keep in Mind

Management

Features
F>M

3rd – 8th

Eyelid

Asymptomatic,

*R/O metastatic

Standard surgical

slow-growing,

mucinous

excision or MMS.

flesh coloured

carcinoma from

soft/spongy

breast or GI tract.

nodule.

Microcystic Adnexal

Face /

Carcinoma

Upper lip

F>M

6th

Slow growing

Perineural

Standard surgical

neoplasm.

invasion is

excision or MMS for

Indurated firm

common

the primary tumour.

plaque or

RT +/- Chemotherapy

discrete nodule.

with perineural

Yellowish to

invasion.

flesh coloured.
Epidermal
surface is
smooth or
crusted.

Adenoid cystic carcinoma

Scalp

F>M

5th

Asymptomatic

Perineural

MMS or resection

crusted

invasion is

with complete

verrucous

common

circumferential

plaque or deep

margin assessment for

seated nodule.

the primary tumour.
RT for perineural
invasion.
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Acrospirocarcinoma

Cylindrocarcinoma

Face

Scalp

F>M

F>M

>5th

>5th

Large ,

Frequently

Standard surgical

ulcerated mass

metastasize to

excision + Sentinel

or nodule or an

regional lymph

node biopsy or neck

infiltrative

nodes + distant

dissection.

plaque

sites

Typically arise

Aggressive

Standard surgical

from a pre-

tumours

excision or MMS for

existing

the primary tumour.

cylindroma with

RT for metastatic

associated rapid

disease or inoperable

growth,

tumours.

tenderness,
ulceration,
discoloration
and/or bleeding.

Syringocystadenocarcinoma

Scalp

M=F

6th

papilliferum

Exophytic

Metastasis is rare.

Standard surgical

verrucous

excision or MMS for

plaque or

the primary tumour.

nodule.

Key. M= Male, F=Female, RT= Radiation therapy, MMS = Mohs micrographic surgery.
Note. Eccrine and apocrine gland carcinomas (*Adapted from Walsh & Santa Cruz,
2011) stratified by area of involvement, gender, age at incidence, clinical features,
notable features and management.
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Table 2.4: Carcinomas of the Hair Follicle*
Common

Gender

Decade

M>F

70th

Clinical Features

Keep in Mind

Management

Slow growing

Metastasis is

Conservative

papule or nodule.

rare.

standard surgical

Site
Tricholemmommal

Head &

carcinoma

Neck

excision or MMS

Proliferating/malignant

Scalp

6th

F>M

tricholemmal cystic
carcinomas

Longstanding

Aggressive

Standard surgical

subcutaneous mass

tumours with a

excision with wide

that has grown

high rate of

margins or MMS

rapidly. Firm,

metastasis

for the primary

painless nodule with

tumour. Neck

overlying alopecia

dissection, RT, and

or ulceration.

chemo has variable
to limited success
for disseminated
tumours.

Matrical carcinoma /

Head &

Malignant pilomatricoma

Neck

4th

M>F

Slow growing, firm,

Metastasis is

Standard surgical

non-tender nodule.

common.

excision with 0.5-

Clinically mistaken

1cm margins or

as a benign

MMS. RT for

pilomatricoma or

metastatic disease

inclusion cyst.

or inoperable
tumours.

Key. M= Male, F=Female, RT= Radiation therapy, MMS = Mohs micrographic surgery.
Note. Carcinomas of the hair follicle (*Adapted from Walsh & Santa Cruz, 2011)
stratified by area of involvement, gender, age at incidence, clinical features, notable
features and management.
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Table 2.5: Carcinomas of the Sebaceous Glands*
Common Site

Gender

Decade

Clinical

Keep in Mind

Management

Slow growing

Classified as

Standard surgical

firm subcutaneous

ocular or

excision with wide

nodule with

extraocular.

margins or MMS

occasional

Associated with

for the primary

ulceration.

Muir-Torre

tumour. Sentinel

Yellow hue is

Syndrome

node biopsy may be

common at

(especially if

useful for poorly

extraocular sites.

diagnosed in

differentiated and

younger patients).

ocular lesions.

Features
Sebaceous carcinoma

Head & Neck,

M>F

Eyelid

70th

Can metastasize.

Key. M= Male, F=Female, RT= Radiation therapy, MMS = Mohs micrographic surgery.
Note: Carcinomas of the sebaceous glands (*Adapted from Walsh & Santa Cruz, 2011)
stratified by area of involvement, gender, age at incidence, clinical features, notable
features and management.

Sarcomas of the Skin
Sarcomas of the skin are a broad group of rare non-epithelial primary skin
neoplasms. These cutaneous neoplasms are classified according to the mature cell type
they resemble. We will focus on three of these neoplasms: the most common sarcoma of
the skin – dermatofibrosarcoma protuberans (DFSP), and the most common cutaneous
sarcoma of the head and neck - atypical fibroxanthoma (AFX), and the most common
vascular sarcoma of the head and neck - cutaneous angiosarcoma (AS) of the face and
scalp.
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Dermatofibrosarcoma protuberans (DFSP).
DFSP is the most common sarcoma of the skin. Its annual incidence has been
estimated at 4.5 cases per 1 million persons in the United States making DFSP nearly half
as common as Merkel Cell Carcinoma (Criscione & Weinstock, 2007). Unlike other rare
skin malignancies this tumour most frequently occurs in the 2nd to 5th decade of life and
affects individuals of African American heritage twice as frequently as Caucasians
(Criscione & Weinstock, 2007; Rouhani et al., 2008).
DFSP is a low-grade sarcoma of fibroblast origin. DFSP is characterized by a
translocation between chromosomes 17 and 22 resulting in the overexpression of plateletderived growth factor receptor β (McArthur, 2004). It is differentiated from a common
dermatofibroma on immunohistochemistry where it is positive for CD34 and negative for
factor XIIIa. Given the characteristically slow growth of these lesions, they typically
present as large tumours. Microscopically, many deep finger-like projections are present
resulting in indistinct borders and recurrence rate as high as 60% (Reinstadler & Sinha,
2012; Stojadinovic et al., 2000). Metastatic disease is uncommon.
Clinical Features and Work-up. Dermatofibrosarcoma protuberans typically
presents as a slow growing flesh-coloured or pink nodular lesion of the trunk or
extremities. Presentation in the head and neck is rare. Over time the tumour develops a
more protruberant appearance. The latest NCCN guidelines (2019d) recommend a deep
subcutaneous punch or incisional biopsy as superficial biopsies may mistakenly suggest
the lesion is a benign dermatofibroma (NCCN, 2019d). Given the low rate of metastasis
imaging is not routinely performed. The NCCN suggests MRI imaging if extensive
extracutaneous extension is suspected (NCCN, 2019d).
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Management. Management is directed by the most recent NCCN guidelines
available from www.NCCN.org (NCCN, 2019d). Mohs micrographic surgery or
surgical excision down to the level of investing fascia with 2-4 cm peripheral margins is
recommended with subsequent complete circumferential margin assessment (i.e.,
intraoperative frozen section analysis) (NCCN, 2019d). Re-resection is recommended
should final pathology demonstrate positive margins (NCCN, 2019d).

Given the

characteristic microscopic extension of DFSP, undermining and/or flap reconstruction
should only be considered once all margins have been histologically cleared (NCCN,
2019d). Radiation therapy and consultation with a multidisciplinary tumour board
should be considered amongst patients with recurrent disease or where complete surgical
excision is not possible (NCCN,2019d). Chemotherapy can be considered in the rare
event of metastatic disease and multidisciplinary tumour board consultation is
recommended in this circumstance (NCCN, 2019d).
Atypical Fibroxanthoma
Atypical fibroxanthoma (AFX) is a very rare low-grade sarcoma of fibroblastic
origin. It typically presents in the head and neck region amongst Caucasian males in their
7th decade of life (Ang et al., 2009; Reinstadler & Sinha, 2012). Similar to other
cutaneous malignancies, AFX presents with increased frequency amongst
immunosuppressed patients. As AFX typically occurs in areas of chronic UV exposure, a
history of previous keratinocyte carcinomas is common, and frequently the AFX is
misdiagnosed clinically as a keratinocyte carcinoma. Due to the rarity of the tumour
there is no incidence data (Reinstadler & Sinha, 2012).
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Similar to Keratinocyte carcinomas, AFX is believed to arise form UV induced
mutations of the p53 tumour suppressor gene (Dei Tos et al., 1994). AFX is
histologically similar to other spindle cell neoplasms such as cutaneous malignant fibrous
histiocytoma (MFH). The distinction between AFX and MFH has been controversial and
in 2002 the World Health Organization recommended the term MFH be replaced by
Undifferentiated pleomorphic sarcoma (UPS) – AFX is considered a distinct pathological
diagnosis to UPS (Bowles et al., 2011). In contrast to AFX, UPS is considered a
diagnosis of exclusion and typically presents as an aggressive subfacial mass of the
extremities amongst older adults. UPS is discussed herein as previous reports of
aggressive AFX lesions may have been incorrectly categorized and would now be
considered UPS.
Clinical Features and Work-Up. AFX typically presents as a slow growing
ulcerated nodule, and as previously mentioned, clinically resembles keratinocyte
carcinoma. On histopathology the lesion is typically confined to the dermis and thus has
limited metastatic potential (Bowles et al., 2011). More aggressive features on
histopathology raise suspicion that the lesion may be an alternative sarcoma such as UPS.
AFX is a diagnosis of exclusion on immunohistochemical analysis and is negative for
S100 protein, cytokeratins, and desmin, differentiating it from melanoma, SCC, and
leiomyosarcoma (Bowles et al., 2011).
Management. Mohs micrographic surgery or surgical excision down to the level
of investing fascia with 1-2 cm peripheral margins is recommended with subsequent
complete circumferential margin assessment (i.e., intraoperative frozen section analysis).
The recurrence rate is approximately 10% for wide local excision and may be lower with
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Mohs micrographic surgery (Reinstadler & Sinha, 2012). To reiterate, nodal or distant
metastasis do not occur with AFX and these findings suggest a more aggressive soft
tissue sarcoma.
Angiosarcomas
Angiosarcomas are very rare vascular sarcomas that include cutaneous
angiosarcoma of the face and scalp. This lesion is considered a high-grade angiosarcoma
and most frequently presents at the scalp or forehead amongst Caucasian men in their 7th
decade of life (Holden et al., 1987). These lesions are highly aggressive and often
multicentric with a high metastasis, recurrence, and mortality rate. Prognosis is poor
with perhaps 12% of patients surviving five or more years (Holden et al., 1987)h.
Vascular endothelial growth factor (VEGF) is involved in the regulation of
endothelial cell proliferation, and VEGF-D levels are significantly elevated amongst
patients with cutaneous angiosarcoma of the face and scalp (Mendenhall et al., 2006).
Clinical Features & Work Up. Cutaneous angiosarcoma of the face and scalp
presents as an ill-defined bruise-like lesion (similar to a hematoma) or as broad facial
edema - especially of the eyelids with minimal erythema (Sangeuza & Requena, 2011).
Induration and ulceration may occur amongst more advanced lesions with some lesions
presenting multifocally (Sangeuza & Requena, 2011).
Tissue sampling can demonstrate immunohistochemical positivity for the
endothelial markers CD34 and CD31, as well as, positive vascular endothelial growth
factor receptor-3 (VEGFR-3), podoplanin, and the proliferation marker K-67 (Orchard et
al., 1996). Tissue biopsies of the periphery of the lesion with testing for the
aforementioned immunohistochemical markers can help determine the extent of the
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tumour (Sangeuza & Requena, 2011). Given the vascular origin of the tumour and the
high propensity for metastasis, imaging of regional lymph nodes and screening for distant
metastases is prudent.
Management. Ideal treatment involves wide excision of the lesion with
subsequent complete circumferential margin assessment (i.e., intraoperative frozen
section analysis) and adjuvant radiotherapy (Sangeuza & Requena, 2011). This is
frequently not possible due to wide extension at the time of diagnosis. Thus, primary
radiation and potentially adjuvant systemic chemotherapy may be the only treatment
option. Nevertheless, referral to a multidisciplinary tumour board is recommended.
Summary
Non-melanoma skin cancers are an extensive group of malignancies. The most
common malignancy is BCC and is fortunately one of the least aggressive and best
managed of the group. The first priority in managing any cutaneous malignancy is
ensuring a complete removal with pathologically clear resection margins. This removal
will undoubtedly result in a facial defect that requires some form of reconstruction to
minimize disfigurement. While some reconstructions result in objectively wellcamouflaged scarring, it is the patient’s perception of the scar that matters most to their
overall wellbeing (Brown et al., 2010). The next chapter will focus on the impact of a
facial scar through the lens of the World Health Organization’s International
Classification of Functioning, Disability, and Health (ICF) (Stephens, 2001).
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Chapter 3: ICF and Skin Scarring
The International Classification of Functioning, Disability, and Health (ICF)
(Stephens, 2001) is a framework for the cataloguing and description of health conditions
and their associated impairments. The ICF strives to integrate the medical model of
focusing on an illness or impairment of a bodily structure or function as a medical
condition with the more contemporary biopsychosocial model of health (Engel, 1977).
By utilizing the biopsychosocial model, it allows for the contextualization of the medical
condition and recognizes the unique psychosocial impact and resultant activity
limitations/participation restrictions that can occur to a particular individual as a result of
the medical condition. For example, focusing medically on a benign facial scar may
ignore its potential psychological ramifications and the degree to which it prevents an
individual from participating in social activities. The ICF framework strives to provide a
more wholistic lens from which we can better understand the true impact of a health
condition. While this framework succeeds in describing many health conditions, it is not
without its own limitations. To this author’s knowledge, no previous investigations have
utilized the ICF framework for describing the health condition or functional impairments
of skin scarring (i.e., congenital, post-traumatic, or postsurgical scarring). The goals of
this chapter are to explore the current application of the ICF model to skin scarring,
highlight previous investigations that apply the principles of ICF framework to skin
scarring, and define areas for future investigation.
Skin Scarring through the ICF model
The ICF describes skin scarring as an impairment in the “repair functions of the
skin” (b820) – “Functions of the skin for repairing breaks and other damage to the skin”
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(Stephens, 2001). This description highlights physiologic dysfunctions of scar formation
– i.e., the “functions of scab formation, healing, scarring; bruising and keloid formation”
(Stephens, 2001). This description captures the underlying impairment in body function
(dysfunction in skin healing physiology) that produces most clinically obvious scars (i.e.,
overabundant wound healing resulting in an overgrown/hypertrophic/keloid scar). Where
this description falls short is in classifying clinically obvious scars resulting from
“normal” wound healing physiology (i.e., a poorly placed/obvious scar, a scar with
uneven texture, a scar with visible surgical markings/suture marks, etc.). To this end, the
ICF applies the body structure classification whereby the “skin of the head and neck” can
be identified to have a structural impairment (s8100) (Stephens, 2001). Thus, the ICF
model can define the health condition of an obvious scar as an impairment of body
function (i.e., a scar resulting from dysfunctional physiology) or simply based on its
presence and subsequent structural impairment of the head and neck region.
Although the ICF succeeds at identifying the presence or absence of an
impairment in body structure or function, it is limited in its ability to stratify these
impairments with respect to severity. Current qualifiers within the ICF stratify
impairments in body structure or function as being “no, mild, moderate, severe, or
complete” problem(s) (Stephens, 2001). This certainly applies in some circumstances
(i.e., complete impairment in this use of one’s left hand), but is limited in its ability to
accurately convey more subtle impairments (i.e., a slightly obvious 2cm forehead scar).
The degree to which an impairment exists undoubtedly influences the extent to which it
causes an activity limitation and/or participation restriction. Thus, the ability to
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accurately stratify the degree of impairment is paramount to effective clinician
communication and outcomes research.
Contemporary Objective Scar Evaluation
The scar literature presents numerous methods for objectively evaluating skin
scarring. Briefly, current scar evaluation scales include: the Vancouver Scar Scale
(Baryza & Baryza, 1995), Patient and Observer Scar Scale (Draaijers et al., 2004),
Manchester Scar Scale (Beausang et al., 1998), Stony Brook Scar Evaluation Scale
(Singer et al., 2007) and the SCAR Scale (Kantor, 2016). Although these scales
generally demonstrate excellent reliability, they force the evaluation of scar dimensions
(i.e., scar colouration) into categories (i.e., normal, pink, red, purple), or along a linear
equal-appearing interval ordinal scale (i.e., 0 to 10). While categorical and linear scaling
may be appropriate for particular scar features, they fail to allow for scaling minor scar
differences – for example how would one categorically scale a scar that is normal with
some pink components. These scales also fail to quantify abstract features – for
example, it would be challenging to apply a numeric scale indicating the degree to which
a scar might distort surrounding facial structures. Additionally, particular scar variables
(i.e., vascularity and pigmentation) have been empirically shown to conform to
curvilinear mathematical models (Brandt et al., 2009), and thus the use of linear ordinal
scaling measures for these variables do not conform to their inherent mathematical
assumptions. Thus, although categorical and ordinal scar evaluation scales may be
reliable, they are inherently insensitive to minor scar differences, have difficulty
quantifying some features, and struggle with mathematical assumptions that may not
apply to all scar variables. These issues consequently impede the ability to classify skin
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scars and also impair the use of these scales in clinician communications or scar
outcomes research.
Visual Analog Scaling
To overcome some of the limitations of current scar evaluation scales, several
attempts have been made to utilize visual analog scaling (Beausang et al., 1998; Singer et
al., 2007). Visual analog scaling employs a line of set length (i.e., 100 mm), and asks
observers to mark where they feel a particular scalable feature falls on that line. This
technique does not require conformity to a particular mathematical model and has been
previously applied in the voice assessment literature in the characterization of abstract
voice dimensions such as voice “pleasantness” (Eadie & Doyle, 2005). Both the
Manchester Scar Scale (MSS) and the Stony Brook Scar Evaluation Scale (SBSES) draw
on this scaling technique as a means of obtaining a gestalt summary score for the overall
appearance of a scar (Beausang et al., 1998; Singer et al., 2007). While the utility of this
method of assessing overall scar appearance cannot be discounted, both the MSS and
SBSES also employ additional ordinal and/or categorical scaling for independent scar
features (i.e., colour, height, width, distortion, texture, etc.) (Beausang et al., 1998; Singer
et al., 2007). In striving to achieve a valid method of scar severity classification,
independent scar features and overall gestalt measures require the use of reliable and
methodologically valid measurement techniques. Thus, there remains a need for the
development of an instrument that can be employed for the universal, valid, and reliable
classification of skin scar severity.
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The Patient’s Perspective
In addition to the aforementioned limitations of clinical scar outcome/assessment
measures, few scar scales include the patient’s own perspective on their scar (Durani et
al., 2009; Idriss & Maibach, 2009). As described earlier, the limitations and restrictions
posed by a scar are based primarily on the individual’s self-perceived severity of their
scar (Brown et al., 2010). A recently developed patient reported outcome (PRO)
instrument – the SCAR-Q – has been validated by Klassen and colleagues (2018) to
address this limitation (Klassen et al., 2018). This tool will help further elucidate the
patient specific outcomes that can be combined with objective scar assessment to yield a
more comprehensive understanding of scar severity and its biopsychosocial impact.
Social Impairment
Notwithstanding the importance of defining the severity of impairment in body
structure and/or function, the ICF seeks to determine the resultant activity limitations
and/or participation restrictions caused by this impairment. To this end, contemporary
research has largely focused on defining the impact of facial scarring on social
interactions (Kapp-Simon, 1986; Pillemer & Cook, 1989; Pope & Ward, 1997; Rumsey et
al., 2004), quality of life (Bock et al., 2006) and psychological well-being (Brown et al.,
2010; Love et al., 1987; Malt & Ugland, 1989; Ramstad et al., 1995; Rumsey et al., 2004;
Sobanko et al., 2015; Tebble et al., 2006). The majority of this research focuses on
children and adolescents with congenital craniofacial abnormalities resulting in facial
disfigurement (i.e., Tessier clefting, cleft lip, facial abnormalities associated with
syndromes, etc.) (Kapp-Simon, 1986; Okkerse et al., 2001; Pope & Ward, 1997; Tessier,
1976) with only a few investigations highlighting acquired facial scarring (i.e., due to
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burns, trauma, or surgical/operative scarring) (Borah & Rankin, 2010; Brown et al., 2008;
Ishii et al., 2009; Kim et al., 2013; Rankin & Borah, 2003; Sobanko et al., 2015; Tebble
et al., 2006; Van Den Elzen et al., 2012). While much of the literature succeeds at
suggesting the impact of facial scarring, to this author’s knowledge none have addressed
this impact utilizing the framework set-forth by the ICF (Stephens, 2001). Further, very
few investigations have specifically inquired into the activity limitations and participation
restrictions of those with facial scarring beyond a superficial discussion of social and/or
vocational activities (Sobanko et al., 2015).
Summary: The Need for a Biopsychosocial Lens
Skin scarring as a health condition identifies flaws in the medical model of health
as this model focuses primarily on diagnosis and treatment and does not conceptualize the
impact of the health condition on the particular individual. As a corollary, scar
evaluation scales have also primarily focused on individual scar features with very few
attempts at evaluating the psychological and social impact of a scar on the affected
individual. The biopsychosocial model of health strives to integrate the health condition
into an individual’s unique psychological and social context. For example, a very visible
facial scar in North America may be viewed as undesirable, depressing, socially isolating
and in need of treatment, whereas the same scar in tribal Africa may be viewed favorably
and as a sign of higher social status.

Thus, the biopsychosocial model of health works

to contextualize the health condition for a particular individual. It is this biopsychosocial
model on which the ICF framework is built with the goal of providing a means for
reviewing health conditions and their associated impairments, activity limitations, and
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participation restrictions. The ICF model thus provides the necessary means for a more
comprehensive understanding of the impact of skin scars.
The very first step in the process of applying the ICF model and understanding the
psychological and social impacts of a scar requires an accurate and consistent means of
evaluating skin scars. Given the previously reviewed limitations of current scar
evaluation scales, the development of a valid scar assessment tool is necessary. Only
through the development of such a tool can the patient reported outcomes and
psychological and social impact be truly understood. Thus, the development of a novel
valid scar evaluation scale is the focus of the next chapter.
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Chapter 4: Preliminary Reliability Analysis of a Novel Scale for the Objective
Evaluation of Linear Scars
Introduction
Surgeons have long sought methods of achieving optimal post-operative surgical
scars. In spite of these efforts, no objective data exists to support scar optimization
techniques. A longstanding challenge in establishing scar optimization techniques centers
on the ability to objectively evaluate scars. While several scar evaluation scales have
been proposed (Baryza & Baryza, 1995; Beausang et al., 1998; Draaijers et al., 2004;
Kantor, 2016; Sullivan et al., 1990; Vercelli et al., 2003), they largely have been limited
by the inconsistent application of the scales, or incorrect assumptions about how scar
dimensions (e.g., pigmentation, vascularity, pliability, etc.) can be assessed relative to the
inherent mathematical limitations of the scar scales themselves (Brandt et al., 2009).
Literature Review and Critical Appraisal
Several publications have summarized contemporary strategies for assessing
postsurgical scars and current scar rating scales (Durani et al., 2009; Idriss & Maibach,
2009; Perry et al., 2010; Roques & Téot, 2007; Vercelli et al., 2003). Briefly, current
scar evaluation scales including the Vancouver Scar Scale, Patient and Observer Scar
Scale, Manchester Scar Scale, Stony Brook Scar Evaluation Scale, and SCAR scale
primarily utilize categorical and/or ordinal scaling methods. Although these scales
demonstrate good-to-excellent between-rater and within-rater reliability, they force the
evaluation of specific scar dimensions (i.e., pigmentation) into categories (e.g., normal,
pink, red, purple), or characterization using a linear, equal-appearing interval ordinal
scale (i.e., 1 to 10). While categorical and linear scaling may be appropriate for particular
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scar dimensions, they fail to allow for scaling minor scar differences across the full
spectrum of scar severity. Furthermore, particular scar variables (i.e., vascularity and
pigmentation) have been empirically shown to conform to curvilinear mathematical
models (Brandt et al., 2009) and, thus, the use of linear, equal-appearing interval scaling
measures for these variables does not conform to their inherent mathematical
assumptions. Thus, although categorical and ordinal scar evaluation scales may be
reliable, they tend to be insensitive to minor scar differences and are inconsistent with
mathematical assumptions that may not apply to all scar dimensions.
To overcome the limitations of categorical and ordinal scar scaling, several
attempts have been made to utilize visual analog scaling (Duncan et al., 2006; Singer et
al., 2007). Visual analog scaling employs a line of set length (i.e., 100mm), and asks
observers to mark where they feel a particular scalable dimension falls on that line;
absolute anchors for a given scale are provided, but in contrast to equal-appearinginterval scales, no intrinsic value is provided to the rater. Both the Manchester Scar Scale
(MSS) and the Stony Brook Scar Evaluation Scale (SBSES) draw on this scaling
technique as a means of obtaining a gestalt summary score for the overall appearance of a
scar. While the utility of this method of assessing overall scar appearance cannot be
discounted, both the MSS and SBSES employ additional ordinal and/or categorical
scaling for independent scar dimensions (i.e., colour, height, width, distortion, texture,
etc.). In striving to define methods to improve surgical scarring, one must employ a scar
evaluation scale that evaluates overall scar appearance but also allows for the accurate
evaluation of independent scar features. As particular scar improvement strategies may
alter unique scar dimensions independently, a valid and practical scar evaluation scale
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must allow for the measurement of each independent variable so that one may be able to
establish the degree that each variable plays in the overall, composite appearance of a
scar. Additionally, it is possible that a given dimension of a scar may carry considerably
greater impact relative to another dimension. Thus, the ability to measure specific
dimensions inherent in a scar, while at the same time assessing the global characteristic of
a scar may provide valuable clinical information on treatment change and efficacy.
Objectives
This investigation sought to build on the limitations of contemporary scar
evaluation scales and generate a scar scale that could be utilized for the valid and reliable
evaluation of independent scar dimensions, as well as, serving to document overall scar
acceptability.
Methods
Participants
Thirty-four adults (25 women, 9 men) ranging in age from 19 to 63 years (Mean:
30 +/-1 year) served as scar observers/evaluator participants. These participant observers
were voluntarily recruited from a population of university students and hospital
employees (i.e., secretaries, therapists, service staff, etc.) who were naïve relative to any
formal exposure to scars or the methods used to evaluate them. The participant observers
included those without personal experience with surgical scarring to avoid any undue
influence of personal bias in evaluating surgical scars as part of this project. Scar
observers were asked to participate in a prospective, randomized evaluation of surgical
scars using the novel scar scale software. Research ethics approval was obtained
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(HSREB# 12501E) and informed consent was obtained from all participant observers
prior to their participation.
Sample size calculation
To achieve meaningful inter-rater and intra-rater assessments, sample size
calculation required a minimum of 23 subjects. That is, a total sample size (N) of 23
individuals was determined to be sufficient to detect the hypothesized effect (r ²=.12) of
within-subject independent variable 81.6 percent of the time using a .05 alpha level,
assuming a within-subject correlation of .30 (Lee, 2014). This sample size was exceeded
during the study.
Design
This investigation was designed as a three-phase study. The first phase involved
the design and development of a novel scar assessment instrument. To allow for
automated pilot testing, the second phase involved the development of a novel computerbased scar evaluation program. The third phase then utilized this novel software to allow
for a prospective and randomized assessment of the novel scale’s reliability and validity.
Phase 1: Scale Development. A review by Durani et al. (2009) thoroughly
discusses current scar scales and makes strong recommendations for the generation of a
novel assessment instrument, including the rigorous methodology required to generate
such an instrument (Durani et al., 2009). Based largely on these recommendations, the
present investigation sought to generate a reliable and valid scar assessment instrument.
The first component of generating a useful scar scale requires the establishment of
the dimensions to be scaled. Such features as the length, width and height of a scar are
reasonable to consider, but these do not provide a complete description of all scar features
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which could also include the colour of a scar, any evidence of surgery (i.e., suture marks),
distortion of surrounding structures (i.e., the eyelid is pulled by a temple scar), etc. To
this end, we reviewed the literature and all contemporary scar assessment instruments in
an effort to better understand the dimensions central to scar evaluation (Baryza & Baryza,
1995; Beausang et al., 1998; Draaijers et al., 2004; Kantor, 2016; Sullivan et al., 1990;
Vercelli et al., 2003). This review established that only scar pigmentation (i.e., the colour
of a scar) was universally scaled. Additional quantifiable physical dimensions and
qualitative subjective dimensions were also included in these instruments, but there was
no consensus across these assessment instruments as to which dimensions provide the
most descriptive information. Given this lack of uniformity, we turned to patients and
experts to further elucidate a reliable list of dimensions central to scar characterization
and evaluation.
Fifty structured qualitative patient interviews took place whereby individuals with
a scar on the face or neck were asked about their scar and the dimensions they felt most
accurately described it. The patient population included any individual presenting to a
tertiary-care skin cancer clinic for post-operative evaluation of a facial reconstructive
procedure resulting in a facial scar (i.e., Mohs closure, scar revision, etc.). Each patient
was invited to voluntarily participate in this short interview. Patients were excluded from
participation if English was not their primary language. All interviews were conducted
independently by the primary author (MGB), whereby the author presented the purpose
of the study and asked patients to comment on the key features that characterized their
scar. A list of critical, patient generated, dimensions were subsequently generated.
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Following the determination of dimensions deemed to be important to patients,
experts were next asked to comment on the dimensions they felt were important to skin
scar evaluation. A structured interview of eight Board Certified Otolaryngologist – Head
and Neck Surgeons (varying in experience from five to twenty-five years), and ten
clinical nurses (varying in experience from one to fifteen years), took place. These
interviews were conducted independently by the primary author (MGB). Each
interviewee was shown a series of linear scars of the face or neck varying in general
severity and then asked to comment on the dimensions they felt were most important to
characterize these scars. This process generated a list of scar dimensions that were
expert-critical.
Next, the investigative team (MGB, CCM, PD) reviewed the patient-critical and
expert-critical scar dimensions. Each dimension was independently assessed for its
relevance, clarity, and validity to the goal of the scar assessment instrument. This
generated a core group of dimensions. Synonymous and similar terms for specific
dimensions (i.e., pigmentation, colouration) were combined and the final wording of the
dimensions to be scaled were then formulated. It is important to recognize that while
individual dimensions were formulated, they were not mutually exclusive which speaks
to the complexity of scar scaling. Nevertheless, this process resulted in a set of eight
observer scalable dimensions (see Table 4.1). Of the eight dimensions, five were similar
to those appearing in previously reported scales – Height, Width, Pliability, Irregularity
and Distortion (Kantor, 2016; Vercelli et al., 2003), taxonomy was change for one
dimension – Discolouration, and two were unique to this investigation –Evidence of
Surgery, and Camouflage. The descriptors/prompts for each dimension were generated
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and agreed upon by the research team. These dimensions were then submitted to an
assessment of their face validity.

Table 4.1: Dimensions assessed in the Scar Scale
Dimension

Description

Width

How thick is the scar?

Height

How raised is the scar?

Discolouration

How much does the colour vary from normal adjacent tissue?
How pliable does the scar appear if moved between your

Pliability
fingers?
Irregularity

How even is the scar along its course (i.e., bumpy, rough, etc.)?

Distortion

How distorted is the skin adjacent to the scar?
Are there any features that make the scar appear operated on?

Evidence of Surgery
(i.e., suture marks, drain marks)?
Camouflage

How obvious is the scar?

Note. Scar Scale Dimension definitions. This list was provided to all scar observers
during their assessments.
Face validity assessment asked a group of 30 volunteer participants (non-medical
professionals varying in age from 23 – 64 years) and who were naïve to the goals of this
investigation what each dimension and descriptor meant to them. Through this process,
the dimensions and prompts were then refined to those appearing in Table 4.1.
Once the set of dimensions for scar evaluation were generated, we reviewed the
literature for the best means of scaling these dimensions. Contemporary scales were
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found to utilize descriptor based categorical scaling, ordinal linear scaling, or visual
analog scaling. Descriptor based categorical scaling requires the scar evaluator to select
the best choice from a group of predetermined, potential options (i.e., the colour of the
scar is: 1 - Red, 2 - Pink, 3 - Blue, etc.). This type of scaling is impractical to a useful
scar assessment instrument as it does not afford a means of grading dimensions (i.e., the
colour of the scar sits somewhere between pink and red and has a bluish tinge). Given
this important limitation, no descriptor based categorical scaling was utilized within our
assessment scale.
In contrast to descriptor scaling, linear ordinal scaling is a means of evaluating a
dimension whereby an evaluator ranks the dimension using a predetermined, equalappearing interval scale (i.e., the redness of the scar is graded 2 out of 10). Typically,
such scales are constructed so that one end of the scale (e.g., “1”) is normal which the
opposite end of the scale (e.g., “10”) represents the most extreme descriptor for a given
dimension. The inherent limitation of utilizing a linear scale is whether the dimension
being measured conforms to the mathematical assumptions of linear scaling. For
example, the dimension of length can be linearly scaled (i.e., the scar is 2 cm vs. 1 cm
long). A challenge occurs when one attempts to assign a linear value to a dimension that
does not grow in a linear fashion (i.e., how much more pigmented is scar A compared to
scar B)? Using this example, a scaled score of 4 cannot be assumed to be half as
pigmented as that of one that is scaled as a 2. The underlying issue in this situation is that
while some dimensions logically grow linearly (e.g., length), many are characterized by
increasing changes that cannot be captured using the linear assumptions that exist for
equal-appearing-interval scales. This question was the basis of a previous investigation
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by our group whereby it was experimentally determined that some dimensions do not
conform to the assumptions of linear scaling (Brandt et al., 2009). Thus, a linear equal
appearing interval scale was not utilized for the creation of our novel scar assessment
instrument.
Relative to categorical or equal-appearing interval methods of measurement,
visual analog scaling requires an evaluator to mark where they feel the item being
measured falls along the full spectrum of a specific dimension – visually represented as a
line of set length between two anchor points. To adequately scale a dimension, the
anchor points must represent extremes for the dimension. For example, an evaluator
would evaluate a scar for how red it appears and then mark a point along a 10 cm line
whereby one anchor point/end of the line indicates “no redness” and the other anchor
point indicates “extremely red”. The infinite choices provided by this visual
representation of the gradient of the scale (the line) provide a means of scaling with no
inherent limitations as to the type of dimension being scaled (i.e., whether the dimension
is linearly quantifiable). The most significant advantage of using VA scaling methods for
assessment of subjective dimensions is that it is appropriate for both those types of scaled
continua that grow linearly as well as those that do not. Thus, VA scaling provides an
ideal means of gathering valid measures of dimensions such as those which characterize
surgical scars. This type of scaling has been successfully applied to the voice perception
literature to evaluate subjective and abstract voice dimensions such as pleasantness or
harshness (Eadie & Doyle, 2002a, 2002b). Given the success found in utilizing this form
of scaling in evaluating abstract dimensions within other areas, the application of a visual
analog scale to the realm of scar assessment is a logical and empirically supported
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progression. As such, two contemporary scar evaluation scales utilize this as a gestalt
summary measure of overall scar appearance with excellent reliability (Duncan et al.,
2006; Singer et al., 2007). Given the utility of visual analog scaling and its application to
the evaluation of subjective difficult to scale dimensions, visual analog scaling was
chosen as the method of dimension scaling for our scar evaluation instrument.
Phase 2: Scar Evaluation Automation. To evaluate dimensions scaled using a
visual analog scale, one typically measures the location of the evaluators marking along
the defined length of the visual analog line (i.e., the evaluator puts a pen mark for
“redness” at a point 7 cm along a 10 cm line, resulting in the score of 7 for that
dimension). If we measured the visual analog ranking of 8 dimensions across 48 scar
photographs, this would require 354 ruler measurements per subject. The application of
this form of scaling would thus render itself impractical for the validation of a scar
assessment instrument requiring a large volume of participants. To meet this challenge,
we recruited the assistance of Dr. Vijay Parsa, School of Communication Sciences and
Disorders, Western University, Canada to facilitate the development of a computer-based
software application (Scar Ratings Software (ScaRS)).
The ScaRS program displays a random photo of a scar and a set of preselected,
but randomly organized dimensions, each with their corresponding gradient lines (see
Figure 4.1). A moveable tab along the gradient line allows participants to scale the
dimension in a visual analog fashion. When all dimensions have been scaled, the subject
can move forward to the next randomly selected photo. Once all photos have been
evaluated, the software reorganizes the images and their resultant dimension scores so
that they can be conveniently tabulated in a spreadsheet.
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Figure 4.1: ScARS - Scar Rating Software

Note. Screenshot of the ScaRS program developed by Dr. Vijay Parsa, PhD, Western
University, Canada. Scalable dimensions appear on the right. A slider allows the visualanalog scaling of each dimension. The question mark appearing to the right of each
dimension provides a written explanation of the dimension being scaled.

Phase 3: Scar Evaluation. With a novel scar assessment scale, dimensions
identified and defined, and a software program developed, this investigation sought to
determine the reliability, validity, responsiveness, interpretability, and feasibility for use
of the scale within a clinical environment. To this end, a prospective and randomized
evaluation took place.
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Procedure
Participants were asked to evaluate 40 high-resolution photos of surgical scars.
These were obtained from a database of patient photographs. All patients consented to
the storage of their photos and the use of these photos for ethics approved research. The
photos were cropped and magnified to demonstrate the scar in its entirety. Any concealer
make-up was removed prior to scar photography. The scars varied by location, size,
shape, color, and presumed texture. Scars were located on the forehead, cheek, upper lip,
lower lip, chin, upper neck, and lower neck, and varied in length from 3 cm to 10 cm. To
ensure ratings were consistent and reliable, eight of the scar images - varying in severity
(determined through a group consensus exercise), were selected as repeat images to be
evaluated twice, resulting in a total set of 48 images. None of the photographs
represented “area” scars; rather, all scars were linear and the result of incisions of varied
length.
For each scar photo, participants were asked to rate the scar across the dimensions
of Height, Width, Discolouration, Pliability, Irregularity, Distortion, Evidence of Surgery,
and Camouflage using the visual analog scale. Participants were provided with a
description of each scar dimension through the testing software. All testing was
performed independently using the novel ScaRS program. Both the order of photo
presentation and the list of scalable dimensions were randomized for each participant.
Observers were allowed to take as much time as necessary to view the photographs and
provide their ratings and were additionally allowed to alter their evaluations throughout
the test. All assessments were conducted in a quiet laboratory used for psychophysical
research and all images were presented via a desktop computer (Sony Vaio) and high-
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resolution color monitor (Samsung MultiSync 1700). Once testing had begun,
participants were not allowed to ask questions of the research team. At the completion of
testing, participants were allowed to ask questions and provide comments to the research
team.
Outcome Measures and Statistical Analysis
All data analyses were performed using PSAWStatistics 18 (IBM, Minneapolis,
MN). Ratings across observers for each scar photograph were pooled to allow for a
determination of the mean and variability of responses. This was done to ensure that the
scaling procedure could evaluate and capture a wide range of scar severity.
Cronbach’s alpha coefficient is widely understood to indirectly indicate the
degree to which a set of items measures a single unidimensional construct. Thus,
Cronbach’s alpha was used to evaluate between-rater/inter-rater agreement across each
scar scale dimension for each individual photo. For the eight scar photos with repeat
evaluations, Cronbach’s alpha scores were also utilized to determine within-rater/intrarater agreement for each scar dimension.
To better understand the influence of using this novel testing software and to
determine the role of familiarity with the use of a visual analog scale, a second data set
was generated whereby the ratings for first two images evaluated by each observer were
eliminated from the data set – as the photographs were presented in random order, the
eliminated ratings were ultimately removed in a randomized fashion. This data set
provided data free of any learning bias and was subsequently compared to the original
data set that included the ratings for all the images.
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Results
All participants completed the evaluation task and required approximately 43 +/3 minutes (Mean +/- Standard Deviation) to complete the ratings for 48 photos (inclusive
of the 8 repeat images). Thus, a total of 13,056 independent ratings were gathered [(#
photos) x (# viewers) x (# dimensions)].
Figure 4.2 graphically demonstrates the mean rating for each of the scar photos
across the dimensions evaluated. This figure illustrates that the scar photographs
demonstrated variability in the severity of the dimensions evaluated. Table 4.2 presents
the overall mean ratings of the scar photos for the dimensions evaluated. This table
illustrates the range of scar severity across the eight dimensions being evaluated. Figure
4.2 and Table 4.2 demonstrate variability of severity amongst the scar photos and the
utilization of the full spectrum of the visual analog scale by the observers.
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Figure 4.2: Mean Scar Photo Ratings

Note. Mean rating for each dimension for each scar photo. Coloured dots represents the
mean ratings for each scar photo for the corresponding dimension. Possible responses
range from 0 to 100 for each dimension. Variation in dimension ratings represents the
spectrum of severity for each dimension across the forty-image data set.
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Table 4.2: Scar Photo Range of Responses
Evidence
Width

Height

Pliability

Discolouration

Irregularity

Distortion

Camouflage
of Surgery

Mean

23.88

15.28

33.17

34.88

26.46

24.02

30.58

45.30

Min

3.62

3.42

13.73

5.71

3.78

3.76

5.26

4.38

Max

75.52

53.03

57.76

73.88

68.03

64.97

92.67

88.60

95%

18.78;

11.64;

29.78;

29.42;

21.41;

19.15;

24.38;

38.08;

CI

28.98

18.93

36.55

40.35

31.52

28.89

36.78

52.52

Note. Range of responses for the overall image data set. Values presented as mean
rating for all images across each of the scaled scar dimensions. Minimum, Maximum,
and 95% Confidence Interval (CI) data is presented.

Possible responses range from 0 to

100 millimeters for each dimension. Variation in responses represents spectrum of
severity for each dimension across the forty-image data set.
Within-rater / intra-rater agreement across the 8 repeated photos is presented in
Table 4.3. These are presented as Cronbach’s alpha coefficients across the 8 repeated
photographs.

Table 4.3: Within-rater agreement for the eight scaled dimensions
Scar Dimensions

Intra-rater Agreement

Width

0.788

Height

0.818

Pliability

0.837

Discoloration

0.744

Irregularity

0.764
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Distortion

0.796

Evidence of Surgery

0.925

Camouflage

0.878

Note. Intra-rater agreements for the eight scalable dimensions presented as Cronbach’s
alpha coefficients.
Table 4.4 provides the between-rater / inter-rater reliability for the 8 scaled
dimensions across the entire set of 40 photos. These are also presented as Cronbach’s
alpha coefficients.

Table 4.4: Between-rater agreement for the eight scaled dimensions
Scar Dimensions

Inter-rater Agreement

Width

0.903

Height

0.898

Pliability

0.904

Discoloration

0.913

Irregularity

0.777

Distortion

0.937

Evidence of Surgery

0.963

Camouflage

0.939

Note. Inter-rater agreements for the eight scalable dimensions presented as Cronbach’s
alpha coefficients.
The original data set was compared to the data set, whereby the first two ratings
were removed (i.e., for the 40 scar photos randomly presented, the first and second photo
data were removed) thus, providing ratings for only 38 photos. This data was evaluated to
52

determine whether unfamiliarity with a visual-analog scale influenced the ratings of scars
across the eight scalable dimensions. Mean ratings for the 8 scalable dimensions for the
40 presented photographs did not vary significantly when the two data sets were
compared.
Discussion
The goals of this investigation included the determination of a core set of scalable
dimensions for the characterization of linear scars, the development of a novel scar
evaluation scale, and the testing of a scar evaluation computer program.
Through rigorous methodology, a core set of scar dimensions were established
(Table 4.1). These dimensions were derived through previously validated contemporary
scales, interview consensus, and face validity testing. The majority of dimensions
demonstrated strong between-rater (Table 4.4) and within-rater (Table 4.3) agreement
amongst a set of 34 participants. Based on these results, it appears that the dimensions
assessed can be scaled in a reliable fashion. While differences in the degree of
consistency did vary by dimension, which is to be expected, overall, raters assessed each
dimension with what would appear to be a relatively stable intrinsic metric. In spite of
these achievements, the dimension of irregularity was found to be the most variable
relative to the other inter-rater correlations. This variability was further supported by the
routine pressing of the definition key – which provided the descriptor – “How even is the
scar along its course (i.e., bumpy, rough, etc.)?”. The need for viewing the definition
suggests face- and content-validity concerns. At the completion of the testing period,
participants were invited to provide feedback and several participants suggested that this
dimension title be changed to “Texture”. During the initial dimension gathering and
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face-validity exercise, “Texture” was indeed suggested as an alternative title to
“Irregularity”, and thus a subsequent study will contrast these two terms to ensure
optimal face-validity going forward.
Post-testing feedback also elucidated an additional dimension that had been
missed in the original dimension gathering process – the concept of scar impact.
Participants suggested that while the scaled dimensions allowed for scar characterization,
they neglected to capture the relevance of the scar– i.e., a small scar on the forehead may
be considered less relevant/impactful than an identical scar of the mid-cheek. The impact
of scar location, its relevance to the surrounding structures, and its relevance to the face
as a whole, are central to the concept of scar severity and thus must be included in a valid
scar outcome measure. Since the time of the outset of this investigation, Godoy and
colleagues (2011) demonstrated that facial lesion size and location to impart a facial
“attractiveness penalty” – with larger and more central facial lesions more negatively
affecting perceived facial attractiveness (Godoy et al., 2011). This finding is consistent
with that identified by our scar observers, and subsequent scar scale development and
validity testing must incorporate the concept of scar “impact” – i.e., how much of an
influence does the scar have on the rest of the face.
In spite of the aforementioned concerns, the scar dimensions of width, height,
pliability, discolouration, distortion, evidence of surgery, and camouflage appear to be
reliably and consistently evaluated using the visual-analog scaling paradigm. This testing
paradigm improves upon the mathematical assumption limitations of previous scar
evaluation scales (Brandt et al., 2009) while also demonstrating superior reliability (see
Table 4.5). Thus, the initial validation of the proposed scar dimensions and testing
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paradigm provides empirical support for the establishment of a novel scar evaluation
scale termed the Scar Camouflage Scale. Planned subsequent investigations will further
validate and refine this scale to ensure clinical reliability, while also integrating the
findings of this investigation.
Table 4.5
Comparison of Scar Camouflage Scale to other Scar Rating Scales*
Scale

Year

VSS

1990

Intra-rater reliability

Inter-rater reliability

Acceptable

Poor to Moderate

(α = 0.71 – 0.79)

(ICC = 0.03 – 0.64)
Good

MSS

1998

N/A
(Spearman’s 0.87)

OSAS

Acceptable

Poor to Moderate

(α = 0.74–0.90)

(ICC = 0.18–0.56)

2004

Good
SBSES

2007

N/A
(Spearman’s 0.73 to 0.85)

SCS

Acceptable to Excellent

Acceptable to Excellent

(α = 0.74 – 0.92)

(α = 0.78 to 0.96)

2013

*Adapted from Vercelli et al., 2003.
Key. VSS = Vancouver Scar Scale; MSS = Manchester Scar Scale; OSAS = Observer
Scar Assessment Scale; SBSES = Stony Brook Scar Evaluation Scale; SCS = Scar
Camouflage Scale, ICC = Intraclass Correlation Coefficient.
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Note. Intra- and inter-rater reliability for contemporary scar evaluation scales. Intra-rater
reliability are presented as Crohnbach’s alpha. Inter-rater reliability presented as
Intraclass Correlation Coefficient, Spearman’s coefficient, or Cronbach’s alpha.

While the initial focus of this investigation sought to identify scar dimensions that
could be scaled and subsequently develop a novel scar scale, a secondary focus was the
development and testing of a novel scar-rating program (ScaRS program). Participants
reported that the software was intuitive and easy to use. Additionally, observers indicated
that the organizational presentation of the scar photograph, along with the series of
dimensions to be rated were easily understood and that the ability to manually adjust the
slider on each dimensional scale facilitated their ability to rate each dimension in an
independent fashion. As such, they reported the ability to quantify the characteristics
inherent to any given scar photograph without difficulty. This general finding suggests
that the ability to employ the current software within a clinical environment is not only
feasible, but of little burden to observers. Furthermore, the substantial time savings of
automated quantifying of visual-analog ratings, the unrestricted incorporation and
manipulation of scalable dimensions, and the randomization of both the scalable
dimensions and photographs presented, provide for an invaluable tool in the evaluation of
scars and/or other features of photographs.

Conclusions
Subjective scar dimensions can be reliably measured using a visual-analog scaling
paradigm. The results achieved provide preliminary empirical support for the validation
of the Scar Camouflage Scale while also suggesting direction for future investigation.
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The ScaRS program provides an intuitive means of photographic evaluation and rating
that can be employed in subsequent validity testing. These achievements establish a
strong foundation for future scar evaluation, with the goal of objectively evaluating scars
and the methods of improving them.
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Chapter 5: Conclusions and Bringing it all Together
Thus far this work has highlighted the most common mechanism for acquiring a
facial scar (i.e., skin cancer), the biopsychosocial implications of facial scarring, and the
elements central to scar evaluation and objective scaling.

This chapter will review and

integrate these concepts, highlight the clinical implications of this work, and discuss
potential directions for future research. Before concluding, a discussion of the limitations
of the present work will be addressed.
Skin Cancer
Skin cancer is a common disease, so frequent that one in every three newly
diagnosed cancers is skin cancer (Vogel, 2018). Canadians are particular susceptible to
this disease with Canada being ranked 19 of 62 countries relative to skin cancer
susceptibility (Vogel, 2018). Primarily due to direct sun exposure, the head and neck
region is the most commonly affected area with up to 80% of skin cancers affecting this
vital region (Subramaniam et al., 2017). As was originally outlined, the burden of facial
skin cancer is substantial and multifactorial on an individual and societal level. Not only
is an individual confronted with the anxiety provoking diagnosis of a cancer, but
frequently the malignancy is obvious and intrinsically disfiguring resulting in social
isolation. Chapter 2 provides a thorough review of contemporary skin cancer
management; the common theme being that surgery is the gold-standard treatment.
Surgery is not benign and without its own morbidities. Surgical patients are anxious
about the surgery itself, the risks associated with the procedure, post-operative healing
concerns, and the prospect of a disfiguring scar (Brandt et al., 2012; Yeung et al., 2014).
Given these morbidities a societal shift has focused on skin cancer risk minimization –
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i.e., avoiding high UV periods, covering up exposed skin, and using sunscreen. In spite
of these minimization strategies, over 3 million cases of non-melanoma skin cancer
present annually worldwide (Vogel, 2018). Thus, a concerted effort continues to focus
on minimizing treatment related morbidity through well-camouflaged reconstructive
surgery and scar minimization.
Facial Scarring
The negative psychological impact of an acquired facial scar has been well
documented (Borah & Rankin, 2010; Brown et al., 2008; Ishii et al., 2009; Kim et al.,
2013; Levine et al., 2005; Rankin & Borah, 2003; Sobanko et al., 2015; Tebble et al.,
2006; Van Den Elzen et al., 2012). Predictably an entire industry has been built around
the aesthetic improvement of scars with limited empiric evidence to support commercial
promises (Brandt et al., 2009). Similar to commerce and in-part to minimize scarring,
many surgical interventions have shifted focus to becoming “minimal access”, “keyhole”, or “incisionless”. Thus, the focus on scar minimization has been paramount in
both medical and para-medical cultures. Surprisingly and in spite of this focus, there has
been no empirically established gold-standard tool for evaluating scars.
Scar Scaling
As highlighted in Chapter 4, contemporary scar scales suffer from conflicts in the
dimensions that are scaled, inconsistencies in how these dimensions are scaled, and are
inherently flawed relative to the mathematical assumptions underlying their scaling
techniques (Brandt et al., 2009). The proposed Scar Camouflage Scale and the rigor by
which its preliminary validity testing was established strives to overcome these
challenges. Key dimensions for scar evaluation were identified and refined through this
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preliminary validity testing and are summarized in Table 5.1. One of the findings from
our preliminary validity testing was that the dimension “Irregularity” was more variably
scaled and based on this finding, “Texture” is proposed as an improved hinge word for
this dimension. Future investigations will need to compare this to the original
“Irregularity” data set. Further, the dimension of “Impact” was proposed as a means of
capturing the effect of the scar on the individual’s overall appearance – a unique
dimension that to our knowledge, has not previously been captured in the scar evaluation
literature.

Table 5.1: Scar Evaluation Dimensions
Dimensions
Width
Height
Pliability
Discoloration
Texture
Distortion*
Evidence of Surgery
Camouflage
Impact**
Note. *Texture replaces “Irregularity” and **Impact is a newly proposed dimension.
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Thus, based on the work highlighted in Chapter 4, empiric evidence has been
established to support the development of the Scar Camouflage Scale as an effective and
reliable means of scar evaluation. Nevertheless, more work must be done to refine this
scale to ensure real-world applicability.
Clinical Implications
While some components of empiric scar scaling appeals to academic curiosity, the
ability to accurately and objectively evaluate a scar forms the foundation for real clinical
work. This is so fundamental, that at present health care providers do not even have an
accurate way of documenting or discussing a scar beyond “it’s good” or “it’s bad”.
Providing an objective and reliable method for documenting scar severity sets the stage
for real-world applicability.
Armed with a reliable scar scale we can begin to understand and appreciate the
factors – both positive and negative – that determine individual scar acceptability. This
knowledge provides the basis for comprehensive pre-operative counselling. Factors
identified as “protective” against negative scar acceptability can potentially be fostered to
improve an individual’s capacity for scar acceptance. Alternatively, the identification of
“hindering” factors can allow for early counselling and intervention. This step provides
the means of moving beyond the scar itself and allowing the integration of the
psychosocial factors that contribute to an individual’s overall well-being and social
participation.
While wholistic patient care is the goal of any medical intervention, a reliable scar
scale also provides the basis for improving scars themselves.

A “good” post-operative

scar is an outcome believed to result from favorable patient wound-healing biology,
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meticulous surgical technique, and conscientious wound aftercare. Curiously, surgical
technique and wound aftercare are non-standardized and largely the dogma of
apprenticeship surgical training. It is not uncommon to hear surgical trainees ask their
expert mentor’s why a particular technique is used and be told “this is how we’ve done it
for decades”. Anecdotal experience has been the longstanding basis of surgical training.
The Scar Camouflage Scale provides an instrument by which surgical wound closure
technique and aftercare can be empirically investigated. Does a particular angle of
incision, suturing technique, type of suture, or aftercare strategy result in superior scars?
Why is it that some surgeons can achieve better scars than others? The answers to these
questions have the potential to fundamentally change the way surgical wounds are closed
and cared for worldwide.
Directions for Future Research
Standardized scar evaluation is the bottleneck to holistically understanding skin
scarring as a health condition. As discussed in Chapter 3, any attempt to apply the ICF
framework or more simply to evaluate the psychosocial consequences of a facial scar
relies on the ability to accurately characterize a scar. We implicitly understand that a
more self-conscious individual will be more psychosocially affected by a scar, but how
self-conscious do they need to be, what is the smallest scar that contributes to this
outcome, and how does this consequence translate to their social or vocational
functioning? The Scar Camouflage Scale provides the necessary basis for addressing
these questions as it provides the fundamental objective quantification of the scar itself.
The scaled scar measurement can then be hinged to multiple demographic features
including age, gender, socioeconomic status, etc., and subsequently compared to
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validated quality of life metrics and patient reported outcome measures to provide truly
meaningful insight on the scar specific factors that most contribute to positive or negative
psychosocial outcomes.
The preliminary testing of the Scar Camouflage Scale included the development
of the SCaRS Rating Software. This provided a time-efficient means of acquiring scar
rating data. While a research tool used in a lab is fundamental to scar characterization
research, prospectively modifying the software to create a scar rating handheld device
application (i.e., iOS, Google, etc.) could provide a means of acquiring massive amounts
of data from a robust worldwide population. This app could potentially allow for the
largest possible scar evaluation study – providing an entirely new way of acquiring scar
evaluation data.
As hinted at previously, how an individual views their own scar is vital to their
acceptance of the scar and the effects of that scar on their social and vocational
functioning (Tebble et al., 2006). The “impact” of the scar on their perceived
appearance and the subsequent ramifications are a critical area for future research.
Further, identifying the relationship between objective and subjective “impact” is critical
to pre-operative patient counselling. To this end, further validity testing is necessary to
determine how well the Scar Camouflage Scale captures an individual’s subjective selfrating of their own scar. Once established, self-ratings of scars can then be compared to
objective evaluations of the same scar by neutral observers. These results alongside
individual demographics and well validated self-consciousness and anxiety outcome
measures such as the Derriford Appearance Scale (Harris & Carr, 2001) will yield critical
information that will change how we understand facial scarring.
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Limitations of the Present Project
The goal of this body of work was to highlight our understanding of facial
scarring and provide a means of improving upon current scar evaluation scales. Like all
research it is not without its limitations.
To allow for scientific rigor and standardization, the photographs of the scars
presented to the participants of the reliability testing of Chapter 4 were exclusively photos
of linear (i.e., straight line) scars of varying severity. As we know, scars come in a
variety of shapes and sizes which can include wide burn scars, narrow surgical scars, or
flat skin graft donor site scars. Thus, the utility of the Scar Camouflage Scale will need
to be determined amongst a more broad range of scars.
The participants who served as scar observers and scar raters in our Scar
Camouflage Scale reliability testing were derived from a population of volunteer
university students, university employees, and hospital workers from Southwestern
Ontario. While the age range of participants was quite broad (19 to 63 years), most of
these participants were women (25 out of 34). It is expected, that perceived scar severity
varies across many factors which may include socioeconomic status, gender, culture,
race, religion, and country. Thus, while our reliability testing demonstrated stable results
even amongst a small pool of participants, result stability may vary when applied to a
larger more diverse population. Further work must thus be done to validate the scar
camouflage scale.
Similar to the aforementioned concerns relative to a particular sample size, the
utility of the Scar Camouflage Scale has not been determined amongst individuals with
scars themselves or professional scar observers. Conceivably acquiring a scar impacts
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how one perceives scar severity. Professional observers – i.e., those who regularly care
for scars as part of their vocation (i.e., nurse, surgeon, etc.) – may view scars differently
than non-professional observers. Perhaps surgically creating scars, visualizing the
outcome of this work, or professionally caring for scars may alter one’s internal gauge for
determining scar outcomes. To this end, further validity testing is necessary within these
population groups and between these population groups as the results define the true
applicability of the Scar Camouflage Scale.
Finally, this work is current as of its writing and is likely not the only
investigation focusing on scar evaluation. While every effort was made to integrate the
latest investigations on scar outcomes, given the velocity of scientific research, it is
possible that a novel and very reliable scar scale could be in the process of validity testing
that is superior to the current work. While this possibility exists, the numerous directions
for future research remain important goals that can be achieved irrespective of the
specific measurement tool applied – albeit the tool must be rigorously validated.

Summary
In summary, facial skin scarring is a substantial problem with a real and tangible
impact on an individual’s self-perceived attractiveness, self-esteem, social acceptance,
and overall societal and vocational functioning. This body of research has reviewed the
challenges associated with facial skin scars, the most common mechanism by which
facial scars are obtained (i.e., skin cancer) and the need for more holistic approaches to
scar characterization and measurement.
The robust development of a novel scar evaluation scale was proposed. It is
encouraging that our preliminary validity testing provides a springboard for future
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research. Findings of this research have the potential to help understand the factors that
impact skin scar development and thereby direct caregivers in their efforts towards scar
minimization. At the same time, future research can be directed to the factors that impact
upon subjective and objective scar characterization and acceptability, ideally with the
goal of improving direct patient counselling both pre- and post-scar development.
In seeking to establish a novel scar evaluation scale, the unique SCaRS Rating
Software was developed. This tool provides a robust, adaptable, and time-efficient means
for acquiring enormous amounts of scar rating data (i.e., nine-dimension measurements
for each scar photo for every scar observer). Thus, we now have the scar rating tool, the
timesaving software, and a means of data acquisition to propel clinical scar research
forward.
In conclusion, this work has provided the background and direction for a robust
program of research into the evolution and impact of scars. Consequently, the outcome
of this research has the potential to impact on every individual who acquires a scar
through any means. While scars may be inevitable, we now have the background and
tools available to minimize the scars of the future and the impact on those we serve.
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Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery.
Niagara Falls, Ontario, Canada. May 2010.
A prospective evaluation of perioperative concern amongst patients considering
thyroidectomy.
Brandt MG, Franklin JH, Osborn HA, Fung K, Yoo J, Doyle PC.
World Congress on Thyroid Cancer. Toronto, Ontario, Canada. August 2009.
A prospective evaluation of perioperative concern amongst patients considering
thyroidectomy.
Brandt MG, Franklin JH, Osborn HA, Fung K, Yoo J, Doyle PC.
Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery.
Halifax, Nova Scotia, Canada. May 2009.
Atrophy amongst mucosa only versus muscular mucosa superiorly based pharyngeal
flaps.
Brandt MG, Husein M, Matic D, Leung A, Wehrli B, Welch I, Doyle PC.
Junior Investigator Competition, Annual American Cleft Palate – Craniofacial Association
Meeting. Scottsdale, Arizona, United States of America. April 2009.
A prospective randomized evaluation of scar assessment measures.
Brandt MG, Moore CC, Micomonaco D, Fung K, Franklin JH, Yoo J, Doyle PC.
Annual Eastern Section Triologic Society Meeting. Boston, Massachusetts, United States
of America. January 2009.
A needs assessment of undergraduate education in Otolaryngology amongst Family
Medicine residents.
Glicksman JT, Brandt MG, Parr J, Fung K.
Annual Meeting of the Canadian Society of Otolaryngology – Head and Neck Surgery.
Jasper, Alberta, Canada. May 2008.
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Clinical evaluation of a novel internal nasal dilation stent for the improvement of
nasal breathing.
Brandt MG, Moore CC, Doyle PC.
Annual Eastern Section Triologic Society Meeting. Philadelphia, Pennsylvania, United
States of America. January 2008.
A randomized control trial of fluorescence guided surgical excision of nonmelanotic
cutaneous malignancies.
Brandt MG, Moore CC, Jordan K.
Poliquin Medtronic-Xomed Resident Research Competition – Annual Meeting of the
Canadian Society of Otolaryngology – Head and Neck Surgery. Kelowna, British
Columbia, Canada. May 2006.
Visual spatial ability, learning modality and surgical knot tying.
Brandt MG, Davies ET.
Annual Meeting of the Royal College of Physicians and Surgeons of Canada. Ottawa,
Ontario, Canada. October 2004.
Medical student career choice and mental rotations ability.
Brandt MG, Wright ED.
Annual Meeting of the Royal College of Physicians and Surgeons of Canada. Ottawa,
Ontario, Canada. October 2004.
Symptoms, acid exposure, and motility in patients with Barrett’s esophagus.
Brandt MG, Darling GE, Miller L.
Annual Meeting of the Canadian Association of Thoracic Surgeons. London, Ontario,
Canada. September 2002.

Peer-Reviewed Posters:
Oyewumi M, Brandt MG, Carrillo B, Atkinson A, Iglar K, Forte V, Campisi P. Objective
evaluation of otoscopy skills among family and community medicine, pediatric, and
Otolaryngology Residents. Annual Meeting of the Canadian Society of Otolaryngology –
Head and Neck Surgery. Charlottetown, Prince Edward Island, Canada.
Roach V, Brandt MG, Moore CC, Wilson TD. The evaluation of 3D videography as a
surgical training tool. 2011 University of Western Ontario Annual Anatomy and Cell
Biology Research Day. London, Ontario, Canada.
Abdul-Sater L, Henry M, Mjovic T, Brandt MG, Franklin JH, Black MJ, Hier MP, Payne
RJ. What are thyroidectomy patients really concerned about? A prospective evaluation of
perioperative concerns amongst patients considering thyroidectomy. 2010 Annual meeting
of the American Academy of Otolaryngology. Boston, Massachusetts, USA.
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Brandt MG, Moore CC, Micomonaco D, Fung K, Franklin JH, Yoo J, Doyle PC. Clinical
evaluation of scars: are we measuring correctly? 2008 Annual meeting of the American
Academy of Facial Plastic and Reconstructive Surgery. Chicago, Illinois, USA.
Brandt MG, Wright ED. Chronic maxillary atelectasis is the silent sinus syndrome. 2007
Combined Otolaryngology Spring Meeting. San Diego, California, USA.

Chaired courses & workshops:
2019

Complications, Pearls & Pitfalls in Facial Reconstruction
Panel Discussion Chair
Co-Presenters: Moore CC, Taylor SM, Ansari K.
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Edmonton, Alberta, June 2019

2019

Case-Based Panel Discussion: Interesting Cases
Panel Discussion Chair
Co-Panelists: Witterick I, Davids T, Lin J
OTOUpdate 2019
Toronto, Ontario, February 2019

2018

Facial Plastic & Reconstructive Surgery Paper Presentations
Paper Presentation Chair
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Quebec City, Quebec, June 2018.

2018

Lumps, Bumps & Looks in the Head and Neck.
Course Director
Accredited 3.5hr CME event covering a broad spectrum of topics in
skin cancer, oral pathology, occuloplastic lesions, facial reconstruction,
and facial aesthetics. Toronto, Ontario, April, 2018

2017

Nasal reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Moore CC, Taylor SM, Ansari K, Hekkenberg R.
Annual Clinical Day of the Canadian Academy of Facial Plastic &
Reconstructive Surgery. Toronto, Ontario, October 2017.

2017

Complications, Pearls & Pitfalls in Facial Reconstruction
Co-Presenters: Moore CC, Taylor SM, Trites J
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Saskatoon, Saskatchewan, June 2017.
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2017

Facial Plastic & Reconstructive Surgery Paper Presentations
Paper Presentation Chair
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Saskatoon, Saskatchewan, June 2017.

2017

Nasal reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Moore CC, Taylor SM, Trites J
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Saskatoon, Saskatchewan, June 2017.

2016

Lumps, Bumps & Looks in the Head and Neck: An update in
Dermatology and Facial Plastic & Reconstructive Surgery.
Course Director
Accredited 3.5hr CME event covering a broad spectrum of topics in
skin cancer, facial reconstruction, and facial aesthetics. Toronto,
Ontario, April, 2017

2016

Nasal reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Moore CC, Taylor SM, Ansari K, Trites J, Bonaparte J.
Annual Clinical Day of the Canadian Academy of Facial Plastic &
Reconstructive Surgery. Toronto, Ontario, October 2016.

2016

Facial reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Tasman A, Taylor SM, Ansari K, Trites J, Moore CC.
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Charlottetown, Prince Edward Island, June 2016.

2016

Caring for skin cancer and facial aesthetics in family practice: An
update in Dermatology and Facial Plastic & Reconstructive
Surgery.
Course Director
Accredited 6.5hr CME event covering a broad spectrum of topics in
skin cancer, facial reconstruction, and facial aesthetics. Toronto,
Ontario, June 2016

2015

Facial reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Moore CC, Taylor SM, Ansari K, Trites J.
Annual Clinical Day of the Canadian Academy of Facial Plastic &
Reconstructive Surgery. Toronto, Ontario, October 2015.
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2015

Facial reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Sykes J, Taylor SM, Ansari K, Trites J.
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Winnipeg, Manitoba, June 2015.

2015

An evidence based approach to nasal trauma.
Co-Presenter: Taylor SM.
Annual Meeting of the Canadian Society of Otolaryngology – Head &
Neck Surgery. Winnipeg, Manitoba, June 2015.

2014

Facial reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Taylor SM, Ansari K, Moore CC, Trites J.
Annual Clinical Day of the Canadian Academy of Facial Plastic &
Reconstructive Surgery. Toronto, Ontario, October 2014.

2012

Facial reconstruction: a specialist panel on the contemporary
reconstruction of the face.
Co-Presenters: Higgins K, Ansari K, Taylor SM, Moore CC.
Annual Meeting of the Canadian Society of Otolaryngology – Head
and Neck Surgery. Toronto, Ontario, May 2012.

2012

A comprehensive review and update in facial plastic surgery.
Co-Presenters: Taylor SM, Ellis DAF, Moore CC
Annual Meeting of the Canadian Society of Otolaryngology – Head
and Neck Surgery. Toronto, Ontario, May 2012.

2011

US fellowships: options, immigration and application explained.
Co-Presenters: Raza SN, Annand S.
Annual Meeting of the Canadian Society of Otolaryngology – Head
and Neck Surgery. Victoria, British Columbia, May 2011.

2011

Local flap reconstruction for the Otolaryngologist – Head and
Neck Surgeon.
Annual Meeting of the Canadian Society of Otolaryngology – Head
and Neck Surgery. Victoria, British Columbia, May 2011.

2011

Upper & lower facial trauma for the Otolaryngologist – Head and
Neck Surgeon.
Annual Meeting of the Canadian Society of Otolaryngology – Head
and Neck Surgery. Victoria, British Columbia, May 2011.
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2010

Facial trauma for the Otolaryngologist – Head and Neck Surgeon.
Co-Presenter: Moore CC.
Annual Meeting of the Canadian Society of Otolaryngology – Head
and Neck Surgery. Niagara Falls, Ontario, Canada. May 2010.

Academic achievements & awards:
2010

2010 Thomas Martin Golden Throat Award
Annual award for the most outstanding scientific presentation amongst
Otolaryngology residents at the University of Western Ontario.

2010

2010 Undergraduate Otolaryngology Teaching Award
Annual award presented by undergraduate medical students to an
Otolaryngology resident for outstanding teaching during their third
year clinical clerkship.

2009

2009 Outstanding Surgical Teaching Award
Quarterly award for the most outstanding surgical resident educator for
medical students completing their clinical clerkship.

2009

2009 C.A. Thompson Award for Scientific Achievement in
Otolaryngology
Annual award for the most outstanding research project amongst
Otolaryngology residents at the University of Western Ontario.

2008

2008 University Students’ Council Teaching Honour Roll: Award
of Excellence – Medicine
Annual university-wide teaching award based upon undergraduate
medical student nominations of a lecturer at the University of Western
Ontario.

2008

2008 C.A. Thompson Award for Scientific Achievement in
Otolaryngology
Annual award for the most outstanding research project amongst
Otolaryngology residents at the University of Western Ontario.

2008

2008 Undergraduate Otolaryngology Teaching Award
Annual award presented by undergraduate medical students to an
Otolaryngology resident for outstanding teaching during their third
year clinical clerkship.

2007

2007 Thomas Martin Golden Throat Award
Annual award for the most outstanding scientific presentation amongst
Otolaryngology residents at the University of Western Ontario.
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2007

2007 Undergraduate Otolaryngology Teaching Award
Annual award presented by undergraduate medical students at the
University of Western Ontario to an Otolaryngology resident for
outstanding teaching during their third year clinical clerkship.

2006

2006 Paediatric Surgery Resident Research Award (Division of
Paediatric Surgery Research Competition)
One of two awards for excellence in Paediatric research amongst
postgraduate trainees at the University of Western Ontario.

2001

Fourth Year Undergraduate Psychology Prize
Awarded to the undergraduate student with the highest GPA amongst
graduating B.Sc. (Specialized Honours) Psychology students at York
University

2001

Bethune College Masters Prize
An annual award to the undergraduate student who has most
contributed to Bethune College (York University)

2000, 2001

Bethune College Masters Honour Roll
An annual award to undergraduate students who have made significant
contributions to Bethune College (York University)

1998 – 2001

Deans Honour Roll
York University

1999

Undergraduate Academic Scholarship
York University

1998

Merit Award
York University

Professional extracurricular activities:
2019 – Present

Scientific Co-Chair
Section of Facial Plastic & Reconstructive Surgery
International Federation of Otolaryngology Societies 2021 Vancouver
Meeting

2018 – Present

Reviewer & Podium Presentation Chair
Facial Plastic & Reconstructive Surgery Podium Presentation & Poster
Submissions
Canadian Society of Otolaryngology Annual Meeting
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2017 – Present

Section of Otolaryngology - Delegate
Ontario Medical Association

2016 – Present

Ontario Regional Representative
Canadian Academy of Facial Plastic & Reconstructive Surgery

2014 – Present

Co-director; Resident Soft-Tissue Dissection Course
Division of Facial Plastic & Reconstructive Surgery
Department of Otolaryngology – Head and Neck Surgery
Faculty of Medicine, University of Toronto

2014 – Present

Ontario Regional Representative
Canadian Society of Otolaryngology – Head and Neck Surgery

2011 – 2017

Fellowship Committee
American Academy of Facial Plastic and Reconstructive Surgery

2010 – 2017

Membership & Residency Relations Committee
American Academy of Facial Plastic and Reconstructive Surgery

2010 – 2017

Research Committee
American Academy of Facial Plastic and Reconstructive Surgery

2015– 2016

Grant Reviewer
Combined Otolaryngology Research Effort (CORE) Grant Review
American Academy of Otolaryngology – Head and Neck Surgery

2010 – 2016

Young Physicians Committee
American Academy of Facial Plastic and Reconstructive Surgery

2014 – 2015

Grant Reviewer
Combined Otolaryngology Research Effort (CORE) Grant Review
American Academy of Otolaryngology – Head and Neck Surgery
American Academy of Facial Plastic & Reconstructive Surgery

2012 – 2016

Electronic Communication Chair
Canadian Society of Otolaryngology – Head and Neck Surgery

2004 – 2011

Interviewer
Schulich School of Medicine Admissions Committee
University of Western Ontario

2008 - 2009

Resident Representative, Postgraduate Education Committee
Department of Otolaryngology, University of Western Ontario
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2007 – 2009

2007

Resident Representative, University of Western Ontario
American Academy of Otolaryngology – Head and Neck Surgery
Resident Representative, Undergraduate Education Committee
Department of Otolaryngology, University of Western Ontario

Volunteerism:
2015

Toronto Indy, Toronto, Ontario, Canada
Ontario Race Physicians - Volunteer Otolaryngology – Head and Neck
Surgeon to the drivers and race teams at the 2015 Toronto Indy. 10hrs.

2015

Pan & Parapan American Games, Toronto, Ontario, Canada
Volunteer Otolaryngology – Head and Neck Surgeon to the athletes
and international delegates to the 2015 Pan Am and Para Pan Am
Games. 25 hrs.

2011

University of Michigan Hope Clinic
Combined University of Michigan Departments of Otolaryngology &
Plastic Surgery charitable clinic for uninsured patients in the Michigan
area.

2009

Medical Mission to La Ceiba, Honduras
University of Michigan medical mission. Provided clinical and
operative care to children and adults affected by conditions of the head
and neck.

Journal reviewer:
2019 – Present

Canadian Medical Association Journal

2017 – Present

Journal of Surgical Education

2012 – Present

Anatomical Sciences Education

2011 – Present

International Forum of Allergy & Rhinology

2010 – Present

American Journal of Rhinology & Allergy

2008 – Present

The Laryngoscope

2007 – Present

Journal of Otolaryngology – Head and Neck Surgery
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Professional memberships:
Canadian Society of Otolaryngology – Head and Neck Surgery (CSOHNS)
American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS)
Canadian Academy of Facial Plastic and Reconstructive Surgery (CAFPRS)
European Academy of Facial Plastic Surgery (EAFPS)
Royal College of Physicians and Surgeons of Canada
Canadian Medical Association (CMA)
Ontario Medical Association (OMA)

Licensure & certification:
2019

Advanced Cardiac Life Support (ACLS®) Provider
Basic Life Support (BLS®) Provider

2011

College of Physicians and Surgeons of Nova Scotia
Independent Medical Practice License: 18085

2018

American Board of Facial Plastic & Reconstructive Surgery
Certification in Facial Plastic & Reconstructive Surgery / Diplomate
ABFPRS

2011

American Board of Facial Plastic & Reconstructive Surgery
Comprehensive Examination in Facial Plastic & Reconstructive
Surgery

2011

College of Physicians and Surgeons of Ontario
Independent Medical Practice License: 82477

2010

Advanced Cardiac Life Support (ACLS®) Provider

2010

Royal College of Physicians and Surgeons of Canada
Fellowship Examination in Otolaryngology – Head and Neck Surgery
(FRCSC)
Membership: 673990

2010

United States of America Drug Enforcement Agency (DEA) Narcotic
License
License: FB2085389
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2010

State of Michigan
Independent Medical Practice License: 4301095791

2009

United States Medical Licensing Examination (USMLE)
Step III

2008

United States Medical Licensing Examination (USMLE)
Step II (CS & CK)

2007

United States Medical Licensing Examination (USMLE)
Step I

2007

Advanced Trauma Life Support (ATLS®) Instructor

2007

Royal College of Physicians and Surgeons of Canada
Principles of Surgery (POS) Examination

2006

Medical Council of Canada (MCC)
Physician Qualifying Examination Part II
Licentiate Number: 101164

2005

College of Physicians and Surgeons of Ontario
Education Practice License: 82477

2005

Medical Council of Canada (MCC)
Physician Qualifying Examination Part I

2005

Laser Fundamentals & Safety Certification

2005

Advanced Trauma Life Support (ATLS®) Provider

2005

Advanced Cardiac Life Support (ACLS®) Provider

Non-academic achievements & awards:
1997

10th Place, Karate, 15th World Maccabiah Games
Tel Aviv, Israel

1996

Black Belt – 1st Dan – Taekwondo
International Taekwondo Federation

1996

Black Stripe – 1st Kyu – Ninjutsu/Ninpo
Genbukan Ninpo Bugei
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